WO2020252598A1 - Radiolabeled compounds targeting the prostate-specific membrane antigen - Google Patents

Radiolabeled compounds targeting the prostate-specific membrane antigen Download PDF

Info

Publication number
WO2020252598A1
WO2020252598A1 PCT/CA2020/050864 CA2020050864W WO2020252598A1 WO 2020252598 A1 WO2020252598 A1 WO 2020252598A1 CA 2020050864 W CA2020050864 W CA 2020050864W WO 2020252598 A1 WO2020252598 A1 WO 2020252598A1
Authority
WO
WIPO (PCT)
Prior art keywords
aromatic
compound
linear
acyclic
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2020/050864
Other languages
English (en)
French (fr)
Inventor
Kuo-Shyan LIN
Francois Benard
Hsiou-ting KUO
Zhengxing Zhang
David Perrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Provincial Health Services Authority
Original Assignee
University of British Columbia
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP20825937.4A priority Critical patent/EP3986872A4/en
Priority to JP2021576163A priority patent/JP7618599B2/ja
Priority to CA3144094A priority patent/CA3144094A1/en
Priority to CN202411581546.0A priority patent/CN119431260A/zh
Priority to AU2020296488A priority patent/AU2020296488A1/en
Priority to KR1020227001449A priority patent/KR20220024595A/ko
Priority to BR112021025810A priority patent/BR112021025810A2/pt
Application filed by University of British Columbia, Provincial Health Services Authority filed Critical University of British Columbia
Priority to CN202080050494.8A priority patent/CN114401947B/zh
Publication of WO2020252598A1 publication Critical patent/WO2020252598A1/en
Priority to US17/371,587 priority patent/US11504441B2/en
Priority to IL288960A priority patent/IL288960B1/en
Anticipated expiration legal-status Critical
Priority to US17/961,299 priority patent/US20230114807A1/en
Priority to JP2025002658A priority patent/JP2025069156A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Definitions

  • the present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen, particularly compounds with low uptake in salivary glands and/or kidneys.
  • PSMA Prostate-specific membrane antigen
  • PSMA is a transmembrane protein that catalyzes the hydrolysis of N-acetyl-aspartylglutamate to glutamate and N-acetylaspartate.
  • PSMA is selectively overexpressed in certain diseases and conditions compared to most normal tissues. For example, PSMA is overexpressed up to 1 ,000-fold in prostate tumors and metastases. Due to its pathological expression pattern, various radiolabeled PSMA- targeting constructs have been designed and evaluated for imaging of PSMA-expressing tissues and/or for therapy of diseases or conditions characterized by PSMA expression.
  • a number of radiolabeled PSMA-targeting derivatives of lysine-urea-glutamate (Lys-ureido-Glu) have been developed, including 18 F-DCFBC, 18 F-DCFPyL, 68 Ga-PSMA-HBED-CC, 68 Ga-PSMA-617, 68 Ga-PSMA I & T (see Figure 1) as well as versions of the foregoing labelled with alpha emitters (such as 225 Ac) or beta emitters (such as 177 Lu or 90 Y).
  • PSMA-617 radiolabeled with therapeutic radionuclides such as 177 Lu and 225 Ac
  • therapeutic radionuclides such as 177 Lu and 225 Ac
  • dry mouth (xerostomia) altered taste and adverse renal events are common side effects of this treatment, due to high salivary gland and kidney accumulation of the radiotracer (Hofman et al., 2018 The Lancet 16(6):825-833; Rathke et al. 2019 Eur J Nucl Med Mol Imaging 46(1): 139-147; Sathekge et al.2019 Eur J Nucl Med Mol Imaging 46(1 ): 129-138).
  • Radiotracer accumulation in the kidneys and salivary gland is therefore a limiting factor that reduces the maximal cumulative administered activity that can be safely given to patients, which limits the potential therapeutic effectiveness of Lys-urea-Glu based radiopharmaceuticals (Violet et al.2019 J Nucl Med. 60(4):517-523).
  • n is 0 or 1 ; each of R 1a , R 1 b and R 1c is independently -CO 2 H, -SO 2 H, -SO 3 H, -SO 4 H, -PO 2 H, -PO 3 H or - PO 4 H; when n is 0, R 2 is -CH 2 -, -CHOH-, -CHF-, -CH 2 CHOH-, -CH 2 CHF- -CH 2 CHOHCH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CHOH-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -,
  • R 2 is -CH 2 -, -CHOH-, -CHF-, -CH 2 CHOH-, -CH 2 CHF- or -(CH 2 ) 2 -;
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 -O-, -S-, -NHC(O)-, -C(O)NH-
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl;
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 9 or R 5 is at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl, or R 10 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1 -3 heteroatoms;
  • R 11 is absent
  • R 12 is I, Br, F, Cl, H, OH, OCH 3 , NH 2 , NO 2 or CH 3 ;
  • Xaa 2 when present, is -N(R 13 )R 14 C(O)-, wherein each R 13 is independently hydrogen or methyl, and wherein each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; and a prosthetic group containing a silicon-fluorine-acceptor moiety.
  • R 0 is O or S
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , OPO 3 H 2 , OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 -B(OH) 2 , or ;R 1c is -CO 2 H, -SO 2 H, -
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -, -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 - - -CH 2 SCH 2 -, -CHFCH 2 CH 2
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl, or alkynylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl, or heteroalkynylenyl;
  • R 4 is -O-, -S-, -Se- -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , , -C(O)- (NH) 2 -C(O)-, -OC(O)NH, -NHC(O)O-, -NHC(O)NH-, -OC(S)NH, -NHC(S)O-, -NHC(S)NH-, - NHC(O)C(O)NH-, -S-S-, -S-CH 2 -S-, -NH-NH-C(O)-, -C(O)-NH-NH;
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl or ethyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkyn
  • R 23 is an optionally substituted C 4 -C 16 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH , N H 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • halogen OMe, SMe, N H 2 , NO 2 , CN, OH, or additional endocyclic ring nitrogen atoms;
  • R 7 is R x -(Xaa 2 ) 0-4 —
  • R 28 is an albumin binder
  • Xaa 2 and Xaa 3 when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 13 is
  • each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl or heteroaryl substituted with a radiohalogen; a prosthetic group containing a trifluoroborate; a prosthetic group containing a silicon-fluorine-acceptor moiety; or a prosthetic group containing a fluorophosphate, fluorosulfate, sulfonylfluoride,
  • R 0 is O; each of R 1a , R 1b and R 1c is independently -CO 2 H, -SO 2 H, -SO 3 H, -SO 4 H, -PO 2 H, -PO 3 H or -PO 4 H;
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 ) -, -C(CH 3 ) 2 CH 2 -, -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 - - -CH 2 SCH 2 -, -CHFCH 2 CH 2
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-,
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or
  • R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl; a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1 -3 heteroatoms; or -CH 2 R 23 , in which R 23 is an optionally substituted C 4 -C 16 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, N H 2 , NO
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 11 is absent
  • R 12 is I, Br, F, Cl, H, OH, OCH 3 , NH 2 , N0 2 or CH 3 ;
  • Xaa 2 when present, is -N(R 13 )R 14 C(O)-, wherein each R 13 is independently hydrogen or methyl, and wherein each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; and a prosthetic group containing a silicon-fluorine-acceptor moiety.
  • PSMA prostate specific membrane antigen
  • R 0 is O or S
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , OPO 3 H 2 , OSO 3 H, -B(OH) 2
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 -B(OH) 2
  • R 1c is -CO 2 H, -SO 2 H, -
  • R 2 is -CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, - CH 2 C(CH 3 )2CH 2 - -CH 2 CH 2 C(CH 3 ) 2 - -CH(CH 3 )-O-CH 2 - -C(CH 3 ) 2 -O-CH 2 - -CH 2 -O-CH(CH 3 )- , -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -S(O)-CH 2 - -CH 2 -S(O) 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -, -C(CH 3 ) 2 -S- CH 2 - -CH 2 -S-CH(CH 3 )-, -CH 2 -S-C(CH 3
  • R 3 is a linker
  • R 0 is O; each of R 1a , R 1 b and R 1c is independently -CO 2 H, -SO 2 H, -SO 3 H, -SO 4 H, -PO 2 H, -PO 3 H or - PO 4 H;
  • R 2 is -CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, - CH 2 C(CH 3 ) 2 CH 2 - -CH 2 CH 2 C(CH 3 ) 2 - -CH(CH 3 )-O-CH 2 - -C(CH 3 ) 2 -O-CH 2 - -CH 2 -O-CH(CH 3 )- , -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -S(O)-CH 2 -, -CH 2 -S(O) 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -CH 2 -,
  • R 3 is a linker
  • R 0 is S or O
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 - -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 -,-CH 2 SCH 2 -, -CHFCH 2 CH 2 -,
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -Se-, -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , -C(O)-
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl or ethyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkyn
  • R 23 is an optionally substituted C 4 -C 1 6 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, NH 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • halogen OMe, SMe, NH 2 , NO 2 , CN, OH, or additional endocyclic ring nitrogen atoms;
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 28 is an albumin binder
  • Xaa 2 and Xaa 3 when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 13 is
  • each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a metal; an aryl or heteroaryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety, a fluorophosphate, a fluorosulfate, or a sulfonylfluoride; and wherein each R 14 is independently:
  • R 0 is S or O
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or ;
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 - -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 -,-CH 2 SCH 2 -, -CHFCH 2 CH 2 -,
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -Se- -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , -C(O)-
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl
  • R 6 is optionally in carbonyl, a phosphoryl or a sulfonyl group that is linked to the alpha-nitrogen in Xaa 1 to respectively give an amide, phosphoramidate/phosphonamidate, or sulfonamide linkage; or alternatively is: -NHC(O)-, -(NH) 2 -C(O)-, -C(O)-(NH) 2 -C(O)-, -OC(O)-, -OC(S)-, -NHC(S)-, - NHC(O)C(O)-, -NH-NH-C(O)-, to enjoin the alpha-nitrogen in Xaa 1 .
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or
  • R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl; a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1-3 heteroatoms;
  • R 23 is an optionally substituted C 4 -C1 6 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, N H 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • halogen OMe, SMe, N H 2 , NO 2 , CN, OH, or additional endocyclic ring nitrogen atoms;
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 28 is an albumin binder; Xaa 2 and Xaa 3 , when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 13 is independently hydrogen or methyl, and wherein each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a metal; an aryl or heteroaryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a pros
  • Various embodiments may be used for imaging PSMA-expressing tissues in a subject.
  • Various embodiments may be used for treatment of a PSMA-expressing condition or disease in a subject.
  • FIGURE 1 shows examples of prior art PSMA-targeting compounds for prostate cancer imaging.
  • FIGURE 2 shows a synthetic scheme for HTK03149 using the solid phase approach.
  • FIGURE 3 shows general synthetic schemes for several example compounds incorporating the Lys-ureido-Aad PSMA-binding moiety.
  • FIGURE 4 shows general synthetic schemes for example compounds with two BF 3 -labeling groups.
  • FIGURE 5 shows reconstructed 68 Ga-labelled PET images of a mouse injected with 68 Ga- HTK03149. Images were obtained at 1 and 3 hours following the intravenous injection of 68 Ga- HTK03149 in immunodeficient mice bearing LNCaP xenografts. The solid arrow points to very high tumor accumulation. The dotted arrow points to minimal kidney accumulation.
  • FIGURE 6 shows the chemical structures of compounds HTK03041 , HTK03149, HTK03169, HTK03161 , HTK03177, HTK03187, HTK03153, HTK03170, HTK03189A, HTK03189B, HTK04033, HTK04036, HTK04037, HTK04040, HTK04041 , HTK04053, HTK03162, and HTK04055.
  • FIGURE 7 shows the maximum intensity projection PET/CT images of 68 Ga-HTK03041 , 68 Ga- HTK03149, 68 Ga-HTK03161 , 68 Ga-HTK03169, 68 Ga-HTK03177, 68 Ga-HTK03187, 68 Ga-HTK03189A, 68 Ga-HTK03189B, 68 Ga-HTK04033, 68 Ga-HTK04036, 68 Ga-HTK04037, 68 Ga-HTK04040, 68 Ga- HTK04041 , and 68 Ga-HTK04053 acquired at 1 h post-injection.
  • FIGURE 8 shows the maximum intensity projection SPECT/CT images of 177 Lu-HTK03149 acquired at 1 h, 4h, 24h, 72h, and 120h post-injection (t: tumor, k: kidney, b: bladder).
  • FIGURE 9 shows the maximum intensity projection SPECT/CT images of 177 Lu-HTK03153 acquired at 1 h, 4h, 24h, 72h, and 120h post-injection (t: tumor, k: kidney, b: bladder).
  • FIGURE 10 shows the maximum intensity projection SPECT/CT images of 177 Lu-HTK03170 acquired at 1 h, 4h, 24h, 72h, and 120h post-injection (t: tumor, k: kidney, b: bladder).
  • FIGURE 11 shows the maximum intensity projection SPECT/CT images of 177 Lu-HTK04028 acquired at 1 h, 4h, 24h, 72h, and 120h post-injection (t: tumor, k: kidney, b: bladder).
  • FIGURE 12 shows the maximum intensity projection SPECT/CT images of 177 Lu-HTK04048 acquired at 1 h, 4h, 24h, 72h, and 120h post-injection (t: tumor, k: kidney, b: bladder).
  • FIGURE 13 shows the maximum intensity projection PET/CT images of 18 F-HTK03162 and 18 F- HTK04055 acquired at 1 h and 2h post-injection (t: tumor, k: kidney, b: bladder).
  • the terms“comprising,”“having”,“including” and“containing,” and grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and/or method steps, even if a feature/component defined as a part thereof consists or consists essentially of specified feature(s)/component(s).
  • composition, use or method excludes the presence of additional elements and/or method steps in that feature.
  • a compound, composition, use or method described herein as comprising certain elements and/or steps may also, in certain embodiments consist essentially of those elements and/or steps, and in other embodiments consist of those elements and/or steps, whether or not these embodiments are specifically referred to.
  • a use or method described herein as comprising certain elements and/or steps may also, in certain embodiments consist essentially of those elements and/or steps, and in other embodiments consist of those elements and/or steps, whether or not these embodiments are specifically referred to.
  • a reference to an element by the indefinite article“a” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements.
  • the singular forms“a”,“an”, and“the” include plural referents unless the context clearly dictates otherwise.
  • the use of the word“a” or“an” when used herein in conjunction with the term“comprising” may mean“one,” but it is also consistent with the meaning of“one or more,”“at least one” and“one or more than one.”
  • the terms“treat”,“treatment”,“therapeutic” and the like includes ameliorating symptoms, reducing disease progression, improving prognosis and reducing recurrence.
  • a“diagnostic agent” includes an“imaging agent”.
  • a“diagnostic radiometal” includes radiometals that are suitable for use as imaging agents.
  • the term“subject” refers to an animal (e.g. a mammal or a non-mammal animal).
  • the subject may be a human or a non-human primate.
  • the subject may be a laboratory mammal (e.g., mouse, rat, rabbit, hamster and the like).
  • the subject may be an agricultural animal (e.g., equine, ovine, bovine, porcine, camelid and the like) or a domestic animal (e.g., canine, feline and the like).
  • the subject is a human.
  • the compounds disclosed herein may also include base-free forms, salts or pharmaceutically acceptable salts thereof. Unless otherwise specified, the compounds claimed and described herein are meant to include all racemic mixtures and all individual enantiomers or com binations thereof, whether or not they are explicitly represented herein.
  • the compounds disclosed herein may be shown as having one or more charged groups, may be shown with ionizable groups in an uncharged (e.g. protonated) state or may be shown without specifying formal charges.
  • the ionization state of certain groups within a compound e.g. without limitation, CO 2 H, PO 3 H 2 , SO 2 H, SO 3 H, SO 4 H, OPO 3 H 2 and the like
  • a carboxylic acid group i.e.
  • COOH would be understood to usually be deprotonated (and negatively charged) at neutral pH and at most physiological pH values, unless the protonated state is stabilized.
  • OSO 3 H i.e. SO 4 H
  • SO 2 H groups SO 3 H groups
  • OPO 3 H 2 i.e. PO 4 H 2
  • PO 3 H groups would generally be deprotonated (and negatively charged) at neutral and physiological pH values.
  • salts and solvate have their usual meaning in chemistry.
  • the compound when it is a salt or solvate, it is associated with a suitable counter-ion.
  • a suitable counter-ion It is well known in the art how to prepare salts or to exchange counter-ions.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of a suitable base (e.g. without limitation, Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are generally carried out in water or in an organic solvent, or in a mixture of the two.
  • Counter-ions may be changed, for example, by ion-exchange techniques such as ion-exchange chromatography. All zwitterions, salts, solvates and counter-ions are intended, unless a particular form is specifically indicated.
  • the salt or counter-ion may be pharmaceutically acceptable, for administration to a subject.
  • suitable excipients include any suitable buffers, stabilizing agents, salts, antioxidants, complexing agents, tonicity agents, cryoprotectants, lyoprotectants, suspending agents, emulsifying agents, antimicrobial agents, preservatives, chelating agents, binding agents, surfactants, wetting agents, non-aqueous vehicles such as fixed oils, or polymers for sustained or controlled release. See, for example, Berge et al. 1977. (J. Pharm Sci.
  • X1-X15, X1-X30, X1-X100, and the like refers to the number of carbons (for alkyls, whether saturated or unsaturated, or aryls) in a compound, R-group or substituent, or refers to the number of carbons plus heteroatoms (for heteroalkyls, whether saturated or unsaturated, or heteroaryls) in a compound, R-group or substituent.
  • Heteroatoms may include any, some or all possible heteroatoms.
  • the heteroatoms are selected from N, O, S, P and Se.
  • the heteroatoms are selected from N, O, S and P.
  • Alkyls and aryls may alternatively be referred to using the expression“Cy-Cz”, where y and z are integers (e.g. C 3 -C 15 and the like).
  • alkyl and heteroalkyl each includes any reasonable combination of the following: (1) saturated alkyls as well as unsaturated (including partially unsaturated) alkyls (e.g. alkenyls and alkynyls); (2) linear or branched; (3) acyclic or cyclic (aromatic or nonaromatic), the latter of which may include multi-cyclic (fused rings, multiple non-fused rings or a combination thereof); and (4) unsubstituted or substituted.
  • an alkyl or heteroalkyl i.e.
  • alkyl/heteroalkyl may be saturated, branched and cyclic, or unsaturated, branched and cyclic, or linear and unsaturated, or any other reasonable combination according to the skill of the person of skill in the art. If unspecified, the size of the alkyl/heteroalkyl is what would be considered reasonable to the person of skill in the art. For example, but without limitation, if unspecified, the size of an alkyl may be 1 ,
  • the size of a heteroalkyl may be 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18,
  • the“alkyl” In the context of the expression“alkyl, alkenyl or alkynyl” and similar expressions, the“alkyl” would be understood to be a saturated alkyl. Likewise, in the context of the expression“heteroalkyl, heteroalkenyl or heteroalkynyl” and similar expressions, the“heteroalkyl” would be understood to be a saturated heteroalkyl.
  • linear alkyl in the context of an alkyl/heteroalkyl group of a compound, the term“linear” may be used as it is normally understood to a person of skill in the art and generally refers to a chemical entity that comprises a skeleton or main chain that does not split off into more than one contiguous chain.
  • linear alkyls include methyl, ethyl, n-propyl, and n-butyl.
  • branched may be used as it is normally understood to a person of skill in the art and generally refers to a chemical entity that comprises a skeleton or main chain that splits off into more than one contiguous chain.
  • the portions of the skeleton or main chain that split off in more than one direction may be linear, cyclic or any combination thereof.
  • Non-limiting examples of a branched alkyl group include tert-butyl and isopropyl.
  • alkylenyl refers to a divalent analog of an alkyl group.
  • alkylenyl, alkenylenyl or alkynylenyl “alkylenyl or alkenylenyl” and similar expressions, the“alkylenyl” would be understood to be a saturated alkylenyl.
  • heteroalkylenyl refers to a divalent analog of a heteroalkyl group.
  • heteroalkylenyl heteroalkenylenyl or heteroalkynylenyl
  • heteroalkylenyl “heteroalkylenyl or heteroalkenylenyl” and similar expressions
  • the“heteroalkylenyl” would be understood to be a saturated heteroalkylenyl.
  • the term“saturated” when referring to a chemical entity may be used as it is normally understood to a person of skill in the art and generally refers to a chemical entity that comprises only single bonds, and may include linear, branched, and/or cyclic groups.
  • Non-limiting examples of a saturated C 1 -C 20 alkyl group may include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n- butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, n-hexyl, i-hexyl, 1 ,2-dimethylpropyl, 2-ethyl propyl, 1-methyl-2-ethylpropyl, l-ethyl-2-methylpropyl, 1 ,1 ,2-trimethylpropyl, 1 , 1 ,2-triethylpropyl, 1 ,1-dimethylbutyl, 2,2-dimethylbutyl, 2-ethylbutyl, 1 ,3-dimethylbutyl, 2- methyl pentyl, 3-methylpentyl
  • the term“unsaturated” when referring to a chemical entity may be used as it is normally understood to a person of skill in the art and generally refers to a chemical entity that comprises at least one double or triple bond, and may include linear, branched, and/or cyclic groups.
  • Non-limiting examples of a C 2 -C 20 alkenyl group may include vinyl, allyl, isopropenyl, l-propene-2-yl, 1- butene-l-yl, l-butene-2-yl, l-butene-3-yl, 2-butene-l-yl, 2-butene-2-yl, octenyl, decenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononanenyl, cyclodecanenyl, and the like.
  • a C 1 -C 20 alkenylenyl therefore encompasses, without limitation, all divalent analogs of the above-listed alkenyl groups.
  • Non-limiting examples of a C 2 -C 20 alkynyl group may include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, and the like.
  • a C 1 -C 20 alkynylenyl therefore encompasses, without limitation, all divalent analogs of the above-listed alkynyl groups.
  • the above-defined saturated C 1 -C 20 alkyl groups, C 2 -C 20 alkenyl groups and C 2 -C 20 alkynyl groups are all encompassed within the term “X 1 -X 20 alkyl”, unless otherwise indicated.
  • the above-defined saturated C 1 -C 20 alkylenyl groups, C 2 -C 20 alkenylenyl groups and C 2 -C 20 alkynylenyl groups are all encompassed within the term X 1 -X 20 alkylenyl”, unless otherwise indicated.
  • the term“X 1 -X 20 heteroalkyl” would encompass each of the above-defined saturated C 1 -C 20 alkyl groups, C 2 -C 20 alkenyl groups and C 2 -C 20 alkynyl gruops, where one or more of the carbon atoms is independently replaced with a heteroatom.
  • the term “X 1 -X 20 heteroalkylenyl” would encompass each of the above-defined saturated C 1 -C 20 alkylenyl groups, C 2 -C 20 alkenylenyl groups and C 2 -C 20 alkynylenyl groups, where one or more of the carbon atoms is independently replaced with a heteroatom.
  • Non-limiting examples of non-aromatic heterocyclic groups include aziridinyl, azetidinyl, diazetidinyl, pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, imidazolinyl, pyrazolidinyl, imidazolydinyl, phthalimidyl, succinimidyl, oxiranyl, tetrahydropyranyl, oxetanyl, dioxanyl, thietanyl, thiepinyl, morpholinyl, oxathiolanyl, and the like.
  • an“aryl” group includes both single aromatic rings as well as fused rings containing at least one aromatic ring non-limiting examples of C 3 -C 20 aryl groups include phenyl (Ph), pentalenyl, indenyl, naphthyl and azulenyl.
  • Non-limiting examples of X 3 -X 20 aromatic heterocyclic groups include pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pirazinyl, quinolinyl, isoquinolinyl, acridinyl, indolyl, isoindolyl, indolizinyl, purinyl, carbazolyl, indazolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, phenazinyl, phenanthrolinyl, perimidinyl, furyl, dibenzofuryl, xanthenyl, benzofuryl, thiophenyl, thianthrenyl, benzothiophenyl, phosphorinyl,
  • substituted alkyl is an alkyl in which one or more hydrogen atom(s) are independently each replaced with an atom that is not hydrogen.
  • chloromethyl is a non-limiting example of a substituted alkyl, more particularly an example of a substituted methyl.
  • Aminoethyl is another non-limiting example of a substituted alkyl, more particularly an example of a substituted ethyl.
  • a substituted compound or group e.g.
  • alkyl, heteroalkyl, aryl, heteroaryl and the like may be substituted with any chemical group reasonable to the person of skill in the art.
  • a hydrogen bonded to a carbon or heteroatom e.g. N
  • halide e.g. F, I, Br, Cl
  • unsubstituted is used as it would normally be understood to a person of skill in the art.
  • Non-limiting examples of unsubstituted alkyls include methyl, ethyl, tert-butyl, pentyl and the like.
  • the expression“optionally substituted” is used interchangeably with the expression “unsubstituted or substituted”.
  • hydrogen may or may not be shown.
  • hydrogens may be protium (i.e. 1 H), deuterium (i.e. 2 H) or combinations of 1 H and 2 H.
  • Methods for exchanging 1 H with 2 H are well known in the art.
  • solvent-exchangeable hydrogens the exchange of 1 H with 2 H occurs readily in the presence of a suitable deuterium source, without any catalyst.
  • acid, base or metal catalysts coupled with conditions of increased temperature and pressure, can facilitate the exchange of non-exchangeable hydrogen atoms, generally resulting in the exchange of all 1 H to 2 H in a molecule.
  • Xaa refers to an amino acid residue in a peptide chain or an amino acid that is otherwise part of a compound.
  • Amino acids have both an amino group and a carboxylic acid group, either or both of which can be used for covalent attachment.
  • the amino group and/or the carboxylic acid group may be converted to an amide or other structure; e.g. a carboxylic acid group of a first amino acid is converted to an amide (i.e. a peptide bond) when bonded to the amino group of a second amino acid.
  • Xaa may have the formula - N(R a )R b C(O)-, where R a and R b are R-groups.
  • R a will typically be hydrogen or methyl.
  • the amino acid residues of a peptide may comprise typical peptide (amide) bonds and may further comprise bonds between side chain functional groups and the side chain or main chain functional group of another amino acid.
  • the side chain carboxylate of one amino acid residue in the peptide e.g. Asp, Glu, etc.
  • the amine of another amino acid residue in the peptide e.g. Dap, Dab, Orn, Lys.
  • “Xaa” may be any amino acid, including proteinogenic and nonproteinogenic amino acids.
  • Non-limiting examples of nonproteinogenic amino acids are shown in Table 1 and include: D-amino acids (including without limitation any D-form of the following amino acids), ornithine (Orn), 3-(1-naphtyl)alanine (Nal), 3-(2- naphtyl)alanine (2-Nal), a-aminobutyric acid, norvaline, norleucine (Nle), homonorleucine, beta-(1 ,2,3- triazol-4-yl)-L-alanine, 1 ,2,4-triazole-3-alanine, Phe(4-F), Phe(4-CI), Phe(4-Br), Phe(4-I), Phe(4-NH 2 ), Phe(4- NO 2 ), homoarginine (hArg), 2-amino-4-guanidinobutyric acid (Agb), 2-amin
  • the wavy line symbol shown through or at the end of a bond in a chemical formula is intended to define the R group on one side of the wavy line, without modifying the definition of the structure on the opposite side of the wavy line.
  • R group is bonded on two or more sides (e.g. R 11 )
  • any atoms shown outside the wavy lines are intended to clarify orientation of the R group. As such, only the atoms between the two wavy lines constitute the definition of the R group.
  • the compound is of Formula I or is a salt or solvate of Formula I:
  • n is 0 or 1 ; each of R 1a , R 1 b and R 1c is independently -C0 2 H, -SO 2 H, -SO 3 H, -SO 4 H, -PO 2 H, -PO 3 H or - PO 4 H; when n is 0, R 2 is -CH 2 -, -CHOH-, -CHF-, -CH 2 CHOH-, -CH 2 CHF- -CH 2 CHOHCH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CHOH-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 - -CH 2 OCH 2 - or -CH 2 SCH 2 -; when n is 1 , R 2 is -CH 2 -, -CHOH-, -CHF-, -CH 2 CHOH-, -CH 2 CHF- or -(CH 2 ) 2 -;
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -NHC(O)-, -C(O)NH-
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 9 or R 5 is at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl, or R 10 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1-3 heteroatoms;
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 1 1 is absent
  • R 12 is I, Br, F, Cl, H, OH, OCH 3 , NH 2 , NO 2 or CH 3 ;
  • Xaa 2 when present, is -N(R 13 )R 14 C(O)-, wherein each R 13 is independently hydrogen or methyl, and wherein each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic
  • the compound of is a salt or solvate of Formula I.
  • the compound of Formula I is a compound of Formula la:
  • R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , R 6 , Xaa 1 and R 7 are as defined for Formula I.
  • the compound is a salt or solvate of Formula la.
  • n is 0. In some embodiments, n is 1.
  • R 1a is -CO 2 H. In some embodiments, R 1b is -CO 2 H. In some embodiments, R 1c is -CO 2 H. In some embodiments, R 1a and R 1b are each -CO 2 H. In some embodiments, R 1a and R 1c are each -CO 2 H. In some embodiments, R 1b and R 1c are each -CO 2 H. In some embodiments, R 1a , R 1b and R 1c are each -CO 2 H. In some embodiments, R 1a , R 1b and R 1c are each -CO 2 H.
  • R 2 is -CH 2 OCH 2 - or -CH 2 SCH 2 -.
  • n is 0 and R 2 is -CH 2 -. In some embodiments, n is 0 and R 2 -CHOH- In some embodiments, n is 0 and R 2 is -CHF-. In some embodiments, n is 0 and R 2 is-CH 2 CHOH- In some embodiments, n is 0 and R 2 is -CH 2 CHF-. In some embodiments, n is 0 and R 2 is - CH 2 CHOHCH 2 -. In some embodiments, n is 0 and R 2 is -CH 2 CHFCH 2 -.
  • n is 0 and R 2 is -(CH 2 ) 2 CHOH- In some embodiments, n is 0 and R 2 is -(CH 2 ) 2 CHF- In some embodiments, n is 0 and R 2 is -(CH 2 ) 3 - In some embodiments, n is 0 and R 2 is -CH 2 OCH 2 -. In some embodiments, n is 0 and R 2 is -CH 2 SCH 2 - [0063] In some embodiments, n is 1 and R 2 is -CH 2 - In some embodiments, n is 1 and R 2 is -CHOH- In some embodiments, n is 1 and R 2 is -CHF-.
  • n is 1 and R 2 is -CH 2 CHOH-. In some embodiments, n is 1 and R 2 is -CH 2 CHF-. In some embodiments, n is 1 and R 2 is -(CH 2 ) 2 -
  • n 0, R 1a is -CO 2 H and R 2 is-(CH 2 )3- In some embodiments, n is 0, R 1a is -CO 2 H and R 2 is-CH 2 - In some embodiments, n is 0, R 1a is -CO 2 H, R 1b is -CO 2 H, R 1c is -CO 2 H, and R 2 is-(CH 2 ) 3 - In some embodiments, n is 0, R 1a is -CO 2 H and R 2 is-CH 2 -
  • R 3 is a linear acyclic C 3 -C 15 alkylenyl. In some embodiments, R 3 is a linear acyclic C 3 -C 15 heteroalkylenyl having 1-5 N, S and/or O heteroatoms. In some embodiments, R 3 is a linear acyclic saturated C 3 -C 10 alkylenyl, optionally substituted with 1-5 amine, amide, oxo, hydroxyl, thiol, methyl or ethyl groups. In some embodiments, R 3 is - (CH 2 ) 3-15 -. In some embodiments, R 3 is - CH 2 -.
  • R 3 is -(CH 2 ) 2 -. In some embodiments, R 3 is -(CH 2 ) 3 -. In some embodiments, R 3 is -(CH 2 ) 4 -. In some embodiments, R 3 is -(CH 2 ) 5 - In some embodiments, R 3 is - CH 2 -O-CH 2 -. In some embodiments, R 3 is -CH 2 -S-CH 2 -.
  • R 4 is -O-. In some embodiments, R 4 is -S-. In some embodiments, R 4
  • R 4 is -NHC(O)-. In some embodiments, R 4 is -C(O)NH-.ln some embodiments, R 4 is . In some embodiments, R 4 is .
  • R 3 is -(CH 2 ) 3-15 - and R 4 is -C(O)NH- In some embodiments, R 3 is - (CH 2 ) 3-5 - and R 4 is -C(O)NH- In some embodiments, R 3 is -(CH 2 ) 4 - and R 4 is -C(O)NH-
  • R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 - In some embodiments, R 5 is -CH(R 10 )-. In some embodiments, R 5 is -CH 2 CH(R 10 )-. In some embodiments, R 5 is -CH(R 10 )CH 2 - In some embodiments, R 5 is -CH(R 10 )-.
  • R 10 is an alkenyl containing either a C 6 -C 16 aryl or X 6 -X 16 heteroaryl having 1-3 heteroatoms independently selected from N, S and/or O.
  • the C 6 -C 16 aryl is benzyl.
  • the X 6 -X 16 heteroaryl is benzyloxyl or benzylthio.
  • R 10 is:
  • R 5 is
  • R 10 is as defined in any embodiment above.
  • R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 - and R 10 is -(CH 2 ) 5 CH 3 . In some embodiments, R 5 is -CH(R 10 )- and R 10 is -(CH 2 ) 5 CH 3 .
  • R 5 is . In some embodiments, R 5 is
  • R 6 is hydrogen. In some embodiments, R 6 is methyl.
  • (Xaa 1 ) 1-4 consists of a single amino acid residue.
  • (Xaa 1 ) 1-4 is a dipeptide, wherein each Xaa 1 may be the same or different.
  • (Xaa 1 ) 1-4 is a tripeptide, wherein each Xaa 1 may be the same, different or a combination thereof.
  • (Xaa 1 ) 1-4 consists of 4 amino acid residues connected by peptide bonds, wherein each Xaa 1 may be the same, different or a combination thereof.
  • each Xaa 1 is independently selected from proteinogenic amino acids and the non-proteinogenic amino acids listed in Table 1 , wherein each peptide backbone amino group is optionally methylated.
  • at least one R 9 is .
  • at least one R 9 is .
  • at least one R 8 is hydrogen.
  • all R 8 are hydrogen.
  • at least one Xaa 1 is a tranexamic acid residue.
  • (Xaa 1 ) 1-4 consists of a single tranexamic acid residue.
  • R 3 is -(CH 2 ) 4 - and -(Xaa 1 ) 1-4 N(R 6 )R 5 R 4 - is
  • R 3 is -(CH 2 ) 4 - and -(Xaa 1 ) 1-4 N(R 6 )R 5 R 4 - is
  • the compound is a compound of Formula II or is a salt or a solvate of Formula II:
  • R 0 is O or S
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or ;
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 -B(OH) 2 , or
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -R0 3 H 2, -B(OH) 2 , or ;
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 - -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 - -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 -,-CH 2 SCH 2 -, -CHFCH 2 CH 2 -, -
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl, or alkynylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl, or heteroalkynylenyl;
  • R 4 is -O-, -S-, -Se-, -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , -C(O)- (NH) 2 -C(O)-, -OC(O)NH, -NHC(O)O-, -NHC(O)NH-, -OC(S)NH, -NHC(S)O-, -NHC(S)NH-, - NHC(O)C(O)NH-, -S-S-, -S-CH 2 -S-, -NH-NH-C(O)-, -C(O)-NH-NH;
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl or ethyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkyn
  • R 23 is an optionally substituted C 4 -C1 6 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, N H 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 28 is an albumin binder
  • Xaa 2 and Xaa 3 when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 13 is
  • each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl or heteroaryl substituted with a radiohalogen; a prosthetic group containing a trifluoroborate; a prosthetic group containing a silicon-fluorine-acceptor moiety; or a prosthetic group containing a fluorophosphate, fluorosulfate, sulfonylfluoride,
  • the compound of Formula II is a compound of Formula I la:
  • R 1a , R 1 b , R 1c , R 2 , R 3 , R 4 , R 5 , R 6 , Xaa 1 and R 7 are as defined for Formula II.
  • the compound is a salt or solvate of Formula lla.
  • R 2 is -CH 2 -. In some embodiments, R 2 is -CH(OH)-. In some embodiments, R 2 is -CHF-. In some embodiments, R 2 is -CF 2 -. In some embodiments, R 2 is - CH(CH 3 )-. In some embodiments, R 2 is -C(CH 3 ) 2 -
  • R 2 is -CH 2 CH(OH)-. In some embodiments, R 2 is -CH 2 CHF-. In some embodiments, R 2 is -CHFCH 2 - In some embodiments, R 2 is -CF 2 CH 2 - In some embodiments, R 2 is - CH 2 CF 2 -. In some embodiments, R 2 is -CH(OH)CH 2 - In some embodiments, R 2 is -CH(CH 3 )CH 2 - In some embodiments, R 2 is -CH 2 CH(CH 3 ) In some embodiments, R 2 is -C(CH 3 )2CH 2 - In some embodiments, R 2 is -CH 2 C(CH 3 ) 2 -
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, - CH 2 CH(OH)-, -CH 2 CHF-, -CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, - CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -, -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, - (CH 2 ) 2 CHF- -(CH 2 ) 3 -, -CH 2 OCH 2 - - -CH 2 SCH 2 -, -CHFC
  • R 2 is -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, - (CH 2 ) 2 CHF- -(CH 2 ) 3 -, -CH 2 OCH 2 -, -CH 2 SCH 2 -, -CHFCH 2 CH 2 -, -CH(OH)CH 2 CH 2 -, - CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, - CH 2 CH 2 C(CH 3 ) 2 -, -CH(CH 3 )-O-CH 2 -, -C(CH 3 ) 2 -O-CH 2 -, -C(CH 3 ) 2 -O-CH 2 -, -C(CH
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, - CHFCH 2 -, -CF 2 CH 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -C(CH 3 ) 2 CH 2 -,-(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF- -(CH 2 ) 3 -, -CH 2 OCH 2 - -CH 2 SCH 2 -, -CHFCH 2 CH 2 -, -CH(OH)CH 2 CH 2 -, -CH(CH 3 )CH 2 CH 2 -, - CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 C(CH 3 ) 2
  • -CH 2 SCH 2 - -CHFCH 2 CH 2 -, -CH(OH)CH 2 CH 2 -, -CH(CH 3 )CH 2 CH 2 - -CH 2 CH 2 CH(CH 3 )-, - C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 CH 2 C(CH 3 ) 2 -, -CH(CH 3 )-O-CH 2 -, -C(CH 3 ) 2 -O-CH 2 -, -CH 2 -O-CH(CH 3 )-, - CH 2 -O-C(CH 3 ) 2 -, -CH 2 -S(O)-CH 2 -, -CH 2 -S(O) 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -, -C(CH 3 ) 2 -S-CH 2 -, -CH(CH 3 )-S-CH 2 -, -C(CH 3 ) 2
  • R 2 is -CH 2 CH(OH)-, -CH 2 CHF-, -CH 2 CH(CH 3 )-, -CH 2 CH(COOH)-, - CH 2 CH(OH)CH 2 -, -CH 2 CH(F)CH 2 -, or -CH 2 CH(CH 3 )CH 2 -, wherein the second carbon in R 2 has R- configuration.
  • R 2 is -CH 2 CH(OH)-, -CH 2 CHF-, or-CH 2 CH(CH 3 )-, wherein the second carbon in R 2 has R-configuration.
  • R 2 is -CH 2 CHF-, wherein the second carbon in R 2 has R-configuration.
  • R 2 is -CH 2 CH(OH)CH 2 - In some embodiments, R 2 is -CH 2 CHFCH 2 - In some embodiments, R 2 is -(CH 2 ) 2 CH(OH)-.
  • R 2 is -(CH 2 ) 2 CHF- In some embodiments, R 2 is -(CH 2 ) 3 - In some embodiments, R 2 is -CH 2 OCH 2 - In some embodiments, R 2 is - CH 2 SCH 2 - In some embodiments, R 2 is -CHFCH 2 CH 2 - In some embodiments, R 2 is - CH(OH)CH 2 CH 2 - In some embodiments, R 2 is -CH(CH 3 )CH 2 CH 2 - In some embodiments, R 2 is - CH 2 CH(CH 3 )CH 2 - In some embodiments, R 2 is -CH 2 CH 2 CH(CH 3 )-.
  • R 2 is - C(CH 3 ) 2 CH 2 CH 2 - In some embodiments, R 2 is -CH 2 C(CH 3 ) 2 CH 2 - In some embodiments, R 2 is - CH 2 CH 2 C(CH 3 ) 2 - In some embodiments, R 2 is -CH(CH 3 )-O-CH 2 - In some embodiments, R 2 is - C(CH 3 ) 2 -O-CH 2 - In some embodiments, R 2 is -CH 2 -O-CH(CH 3 )-.
  • R 2 is - CH 2 -O-C(CH 3 ) 2 - In some embodiments, R 2 is -CH 2 -S(O)-CH 2 - In some embodiments, R 2 is -CH 2 - S(O) 2 -CH 2 - In some embodiments, R 2 is -CH(CH 3 )-S-CH 2 - In some embodiments, R 2 is -C(CH 3 ) 2 - S— CH 2 — . In some embodiments, R 2 is -CH 2 -S-CH(CH 3 )-.
  • R 2 is -CH 2 -S- C(CH 3 ) 2 - In some embodiments, R 2 is -CH(CH 3 )-S(O)-CH 2 - In some embodiments, R 2 is -C(CH 3 ) 2 - S(O)-CH 2 - In some embodiments, R 2 is -CH 2 -S(O)-CH(CH 3 )-.
  • R 2 is -CH 2 - S(O)-C(CH 3 ) 2 - In some embodiments, R 2 is -CH(CH 3 )-S(O) 2 -CH 2 - In some embodiments, R 2 is - C(CH 3 ) 2 -S(O) 2 -CH 2 - In some embodiments, R 2 is -CH 2 -S(O) 2 -CH(CH 3 )-. In some embodiments, R 2 is -CH 2 -S(O) 2 -C(CH 3 ) 2 - In some embodiments, R 2 is -CH 2 -NH-C(O)-. In some embodiments, R 2 is - C(O)— NH— CH 2 — . In some embodiments, R 2 is -C(O)-NH-CH(CH 3 )-. In some embodiments, R 2 is - C(O)-NH-C(CH 3 ) 2 -.
  • the compound is a compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of Formula III or of a salt or a solvate of Formula III:
  • PSMA prostate specific membrane antigen
  • R 0 is O or S
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 -B(OH) 2 , or
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 -B(OH) 2 , or
  • R 2 is -CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, - CH 2 C(CH 3 )2CH 2 - -CH 2 CH 2 C(CH 3 ) 2 - -CH(CH 3 )-O-CH 2 - -C(CH 3 ) 2 -O-CH 2 - -CH 2 -O-CH(CH 3 )- , -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -S(O)-CH 2 - -CH 2 -S(O) 2 -CH 2 -, -CH(CH 3 )-S-CH 2 -, -C(CH 3 ) 2 -S- CH 2 - -CH 2 -S-CH(CH 3 )-, -CH 2 -S-C(CH 3
  • R 3 is a linker
  • the PSMA-targeting moiety of Formula III is a PSM A- targeting moiety of Formula Ilia:
  • R 1a , R 1 b , R 1c , R 2 , and R 3 are as defined for Formula III.
  • the PSMA- targeting moiety is a salt or solvate of Formula Ilia.
  • the linker (R 3 ) may be any linker.
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl, or alkynylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl, or heteroalkynylenyl.
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl.
  • R 3 is a linear or branched peptide linker.
  • R 2 is -CH(CH 3 )CH 2 CH 2 - -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, - C(CH 3 ) 2 CH 2 CH 2 - -CH 2 C(CH 3 ) 2 CH 2 - -CH 2 CH 2 C(CH 3 ) 2 - -CH(CH 3 )-O-CH 2 - -C(CH 3 ) 2 -O-CH 2 - - CH 2 -O-CH(CH 3 )-, -CH 2 -O-C(CH 3 ) 2 - -CH 2 -S(O)-CH 2 - -CH 2 -S(O) 2 -CH 2 -, -CH(CH 3 )-S-CH 2 - - C(CH 3 ) 2 -S-CH 2 - -CH 2 -S-CH(CH 3 )-, -CH 2 -S-C(CH 3 ) 2 -
  • R 2 is -CH(CH 3 )CH 2 CH 2 - In some embodiments, R 2 is - CH 2 CH(CH 3 )CH 2 - In some embodiments, R 2 is -CH 2 CH 2 CH(CH 3 )-. In some embodiments, R 2 is - C(CH 3 ) 2 CH 2 CH 2 -.
  • R 2 is -CH 2 C(CH 3 ) 2 CH 2 - In some embodiments, R 2 is - CH 2 CH 2 C(CH 3 ) 2 - In some embodiments, R 2 is -CH(CH 3 )-O-CH 2 - In some embodiments, R 2 is - C(CH 3 ) 2 -O-CH 2 - In some embodiments, R 2 is -CH 2 -O-CH(CH 3 )-. In some embodiments, R 2 is - CH 2 -O-C(CH 3 ) 2 - In some embodiments, R 2 is -CH 2 -S(O)-CH 2 - In some embodiments, R 2 is -CH 2 - S(O) 2 -CH 2 -.
  • R 2 is -CH(CH 3 )-S-CH 2 - In some embodiments, R 2 is -C(CH 3 ) 2 - S-CH 2 -. In some embodiments, R 2 is -CH 2 -S-CH(CH 3 )-. In some embodiments, R 2 is -CH 2 -S- C(CH 3 ) 2 -. In some embodiments, R 2 is -CH(CH 3 )-S(O)-CH 2 - In some embodiments, R 2 is -C(CH 3 ) 2 - S(O)-CH 2 - In some embodiments, R 2 is -CH 2 -S(O)-CH(CH 3 )-.
  • R 2 is -CH 2 - S(O)-C(CH 3 ) 2 -. In some embodiments, R 2 is -CH(CH 3 )-S(O) 2 -CH 2 - In some embodiments, R 2 is - C(CH 3 ) 2 -S(O) 2 -CH 2 -. In some embodiments, R 2 is -CH 2 -S(O) 2 -CH(CH 3 )-.
  • R 2 is -CH 2 -S(O) 2 -C(CH 3 ) 2 - In some embodiments, R 2 is -C(O)-NH-CH 2 - In some embodiments, R 2 is - C(O)-NH-CH(CH 3 )-. In some embodiments, R 2 is -C(O)-NH-C(CH 3 ) 2 -. [0094] In some embodiments, R 2 is -CH 2 CH(CH 3 )CH 2 -, wherein the second carbon in R 2 has R- configuration.
  • the compound further comprises one or more radiolabeling groups connected to the linker, independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl or heteroaryl substituted with a radiohalogen; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety, a fluorophosphate, a fluorosulfate, or a sulfonylfluoride.
  • the compound comprises a radiometal chelator.
  • the radiometal chelator is bound by a radiometal.
  • the compound comprises an aryl substituted with a radiohalogen.
  • the compound comprises a prosthetic group containing a trifluoroborate. In some embodiments, the compound comprises a prosthetic group containing a silicon-fluorine-acceptor moiety. In some embodiments, the compound comprises a prosthetic group containing a fluorophosphate. In some embodiments, the compound comprises a prosthetic group containing a fluorosulfate. In some embodiments, the compound comprises a prosthetic group containing a sulfonylfluoride. In some embodiments, a fluorine in the aforementioned groups is 18 F.
  • the one or more radiolabeling groups comprise: a radiometal chelator optionally bound by a radiometal; and a prosthetic group containing a trifluoroborate, optionally wherein 1 , 2 or 3 fluorines in the trifluoroborate are 18 F.
  • the compound comprising a PSMA-targeting moiety of Formula III is a compound of Formula II (or Formula I la) or is a salt or solvate of Formula II (or Formula lla), wherein R 2 is -CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 - -CH 2 CH 2 C(CH 3 ) 2 -, -CH(CH 3 )-O-CH 2 -, -C(CH 3 ) 2 -O-CH 2 -, -CH 2 -O-CH(CH 3 )-, -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -O-C(CH 3 ) 2 -, -CH 2 -
  • R 0 is O. In other embodiments, R 0 is S. [00100] In some embodiments, R 1a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , or -
  • R 2a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, or -PO 3 H 2 .
  • R 3a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, or-PO 3 H 2 .
  • R 1a is -CO 2 H.
  • R 1b is -CO 2 H.
  • R 1c is -CO 2 H.
  • R 1a and R 1b are each -CO 2 H.
  • R 1a and R 1c are each -CO 2 H.
  • R 1b and R 1c are each -CO 2 H.
  • R 1a , R 1b and R 1c are each -CO 2 H.
  • R 1a , R 1b and R 1c are each -CO 2 H.
  • R 1a , R 1b and R 1c are each -CO 2 H.
  • R 1a , R 1b and R 1c are anionic or metallated salts of the foregoing
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl.
  • R 3 is a linear acyclic C 3 -C 15 alkylenyl. In some embodiments, R 3 is a linear acyclic C 3 -C 15 alkylenyl in which 1-5 carbons are replaced with N, S and/or O heteroatoms. In some embodiments, R 3 is a linear acyclic saturated C 3 -C 10 alkylenyl, optionally substituted with 1-5 amine, amide, oxo, hydroxyl, thiol, methyl or ethyl groups. In some embodiments, R 3 is - (CH 2 ) 3-15 -.
  • R 4 is -O-. In some embodiments, R 4 is -S-. In some embodiments, R 4 is -NHC(O)-. In some embodiments, R 4 is -C(O)NH- In some embodiments, R 4 is . In some embodiments, R 4 is . In some embodiments, R 4 is -S(O)-. In some embodiments, R 4 is -S(O) 2 -. In some embodiments, R 4 is -C(O)-(NH) 2 -C(O)-. In some embodiments, R 4 is -OC(O)NH- In some embodiments, R 4 is -NHC(O)C-.
  • R 4 is - NHC(O)NH-. In some embodiments, R 4 is -OC(S)NH. In some embodiments, R 4 is -NHC(S)O- In some embodiments, R 4 is -NHC(S)NH-. In some embodiments, R 4 is -NHC(O)C(O)NH- In some embodiments, R 4 is -S-S-. In some embodiments, R 4 is -S-CH 2 -S-. In some embodiments, R 4 is -NH- NH-C(O)-. In some embodiments, R 4 is or -C(O)-NH-NH-.
  • R 3 is - (CH 2 ) 3-15 - and R 4 is -C(O)NH- In some embodiments, R 3 is -(CH 2 )3-5- and R 4 is -C(O)NH-. In some embodiments, R 3 is -(CH 2 ) 4 - and R 4 is -C(O)NH- [00105] In some embodiments, R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 - In some embodiments, R 5 is - CH(R 10 )-. In some embodiments, R 5 is -CH 2 CH(R 10 )-. In some embodiments, R 5 is -CH(R 10 )CH 2 - In some embodiments, R 5 is -CH(R 10 )-.
  • R 10 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl; a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1-3 heteroatoms.
  • R 10 is -CH 2 R 23 , in which R 23 is an optionally substituted C 4 -C 16 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, NH 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups.
  • R 10 is
  • R 10 is an alkenyl containing either a C 6 -C 16 aryl or X 6 -X 16 heteroaryl having 1-3 heteroatoms independently selected from N, S and/or O.
  • the C 6 -C 16 aryl is benzyl.
  • the X 6 -X 16 heteroaryl is benzyloxyl or benzylthio.
  • R 10 is: [001 11] . In some embodiments,
  • R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is
  • R 10 is In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In some embodiments, R 10 is . In
  • R 10 is . In some embodiments, R 10 is:
  • R 10 is
  • R 5 is
  • R 10 is as defined in any embodiment above.
  • R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH2)o-3- and R 10 is -(CH 2 ) 5 CH 3 .
  • R 5 is -CH(R 10 )- and R 10 is -(CH 2 ) 5 CH 3 .
  • R 5 is -(CH 2 ) 0- 3 CH(R 10 )(CH 2 ) 0-3 -.
  • R 10 is -CH 2 -R 23 .
  • R 23 is phenyl substituted with 1 or 2 iodo groups and optionally further substituted with 1 oxy group.
  • R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 - wherein R 10 1S -CH 2 R 23 and R 23 is phenyl substituted with 1 or 2 iodo groups
  • R 23 is .
  • R 23 is . In some embodiments, R 23 is . In some embodiments,
  • R 23 is . In some embodiments, R 23 is . In some embodiments, R 23 is . In some embodiments, R 23 is . In some embodiments, R 23 is . In some embodiments, R 23 is . In some embodiments, R 23 is
  • At least one R 9 or R 5 is . In some embodiments, at least one R 9 or R 5 is . In some embodiments, at least one R 9 or R 5 is
  • R 5 is . In some embodiments, R 5 is . In some embodiments, R 5 is . In some embodiments, R 5 is
  • R 6 is hydrogen. In some embodiments, R 6 is methyl. In some embodiments, R 6 is ethyl.
  • (Xaa 1 )i-4 consists of a single amino acid residue.
  • (Xaa 1 )i-4 is a dipeptide, wherein each Xaa 1 may be the same or different.
  • (Xaa 1 ) 1 -4 is a tri peptide, wherein each Xaa 1 may be the same, different or a combination thereof.
  • (Xaa 1 ) 1-4 consists of 4 amino acid residues connected by peptide bonds, wherein each Xaa 1 may be the same, different or a combination thereof.
  • each Xaa 1 is independently selected from proteinogenic amino acids and the non-proteinogenic amino acids listed in Table 1 , wherein each peptide backbone amino group is optionally methylated.
  • At least one R 9 is R 24 -R 25 -R 26 , wherein R 24 -R 25 -R 26 are independently selected from: -(CH 2 ) 0-3 -; C 3 -C 8 cycloalkylene in which 0-3 carbons are replaced with N, S or O heteroatoms, and optionally substituted with one or more OH, NH 2 , N0 2 , halogen, C 1 -C 6 alkyl and/or C 1 -C 6 alkoxyl groups; and C 4 -C 16 arylene in which 0-3 carbons are replaced with N, S or O heteroatoms, and optionally substituted with one or more OH, NH 2 , NO 2 , halogen, C 1 -C 6 alkyl and/or C1- C 6 alkoxyl groups.
  • (Xaa 1 ) 1-4 is (Xaa 1 ) 0-3 N H R 27 C(O) , wherein R 27 is .
  • at least one R 9 is .
  • at least one R 9 is .
  • at least one R 9 is .
  • at least one R 8 is hydrogen.
  • all R 8 are hydrogen.
  • at least one Xaa 1 is a tranexamic acid residue.
  • (Xaa 1 ) 1-4 consists of a single tranexamic acid residue.
  • R 3 is -(CH 2 ) 4 - and -(Xaa 1 )i-4N(R 6 )R 5 R 4 - is
  • R 10 is any R 10 defined above.
  • R 10 is -CH 2 -R 23 and R 23 is phenyl substituted with 1 or 2 iodo groups and optionally further substituted with 1 oxy group.
  • R 3 is -(CH 2 ) 4 - and -(Xaa 1 )i-4N(R 6 )R 5 R 4 - is
  • R 10 is any R 10 defined above.
  • R 10 is -CH 2 -R 23 and R 23 is phenyl substituted with 1 or 2 iodo groups and optionally further substituted with 1 oxy group.
  • I/I a compounds or salt/solvates thereof
  • all Formula I I/I la compounds or salts/solvates thereof
  • compounds comprising a PSMA-targeting moiety of Formula lll/llla ora salts/solvates thereof.
  • the following definitions therefore apply to compounds comprising Formula lll/llla PSMA-targeting moieties, including but not necessarily limited to when such compounds are Formula ll/lla compounds.
  • R 7 may include a radiolabeling group optionally spaced apart using an amino acid or peptide linker. Accordingly, in some embodiments R 7 is R x -(Xaa 2 )o-4-, wherein R x bonds to the N- terminus of the N-terminal Xaa 2 or an amino acid group of Xaa 2 capable of forming an amide bond (e.g. a side chain of an alpha amino acid).
  • An example of a Xaa 2 sidechain capable of forming an amide bond with R x is an amino group.
  • Non-limiting examples of amino acid residues capable of forming an amide with R x include Lys, Orn, Dab, Dap, Arg, homo-Arg, and the like.
  • Xaa 2 is absent.
  • R 7 may include two radiolabeling groups in which the amino acid or peptide linker provides two attachment points for the radiolabeling groups. Accordingly, in some embodiments, R 7 is .
  • a first R x may bond to the N-terminus of the N- terminal Xaa 2 and a second R x may bond to a side chain functional group (e.g. an amino group) of a Xaa 2 .
  • both R x groups may bond to different Xaa 2 side chains or other functional groups.
  • R 7 may include both a radiolabeling group and an albumin-binding group.
  • R 7 is
  • the albumin bindg group R 28 may be any albumin binding group.
  • the albumin binding group R 28 is
  • the albumin binding group R 28 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
  • the albumin binding group R 28 is , wherein R 12 is I, Br, F, Cl, H, OH, OCH 3 , NH 2 , NO 2 or CH 3 .
  • R 7 is , wherein when (Xaa 2 ) 0-4 is
  • R 7 is , wherein when
  • (Xaa 2 ) 0-4 is (Xaa 2 ) 1-4 then R x bonds to the N-terminus of the N-terminal Xaa 2 or an amino group of Xaa 2 (e.g. a side chain of an alpha amino acid) capable of forming an amide bond.
  • an amino group of Xaa 2 e.g. a side chain of an alpha amino acid
  • R 7 is , wherein when
  • (Xaa 2 ) 0-4 is (Xaa 2 ) 1-4 then R x bonds to the N-terminus of the N-terminal Xaa 2 or an amino group of Xaa 2 (e.g. a side chain of an alpha amino acid) capable of forming an amide bond.
  • an amino group of Xaa 2 e.g. a side chain of an alpha amino acid
  • R 11 is absent. In some embodiments, R 11 is . In
  • R 11 is . in some embodiments, R 11 is . In some
  • R 11 is . In some embodiments, R 11 is . In some embodiments, R 11 is . In some embodiments, R 11 is . In some embodiments, R 11 is
  • R 11 is . In some embodiments, R 11 is
  • R 12 is ortho. In some embodiments, R 12 is para. In some embodiments, R 12 is meta. In some embodiments, R 12 is iodine. In some embodiments, R 12 is fluorine. In some embodiments, R 12 is chlorine. In some embodiments, R 12 is hydrogen. In some embodiments, R 12 is hydroxide. In some embodiments, R 12 is OCH 3 . In some embodiments, R 12 is NH 2 . In some embodiments, R 12 is NO 2 . In some embodiments, R 12 is CH 3 . In some embodiments, R 12 is CH 3 in para position. In some embodiments, R 12 is iodine in para position. In some embodiments, R 12 is chlorine in para position. In some embodiments, R 12 is OCH 3 in para position.
  • Xaa 2 is absent.
  • (Xaa 2 ) 0-4 is a single amino acid residue.
  • (Xaa 2 ) 0-4 is a dipeptide, wherein each Xaa 2 may be the same or different.
  • (Xaa 2 ) 0-4 is a tripeptide, wherein each Xaa 2 may be the same, different or a combination thereof.
  • (Xaa 2 ) 0-4 consists of 4 amino acid residues connected by peptide bonds, wherein each Xaa 2 may be the same, different or a combination thereof.
  • each Xaa 2 is independently selected from proteinogenic amino acids and the non- proteinogenic amino acids listed in Table 1 , wherein each peptide backbone amino group is optionally methylated.
  • each R 13 in (Xaa 2 ) 1-4 is hydrogen.
  • at least one R 13 in (Xaa 2 ) 1-4 is methyl.
  • at least one R 14 in (Xaa 2 ) 1-4 is -(CH 2 ) 2 [0(CH 2 ) 2 ] 1-6 - (e.g. when Xaa 2 is a residue of Amino-dPEGTM 4 -acid or Amino-dPEGTM 6 -acid).
  • Xaa 3 is absent.
  • (Xaa 3 ) 0-4 is a single amino acid residue.
  • (Xaa 3 ) 0-4 is a dipeptide, wherein each Xaa 3 may be the same or different.
  • (Xaa 3 ) 0-4 is a tripeptide, wherein each Xaa 3 may be the same, different or a combination thereof.
  • (Xaa 3 ) 0-4 consists of 4 amino acid residues connected by peptide bonds, wherein each Xaa 3 may be the same, different or a combination thereof.
  • each Xaa 3 is independently selected from proteinogenic amino acids and the non- proteinogenic amino acids listed in Table 1 , wherein each peptide backbone amino group is optionally methylated.
  • each R 13 in (Xaa 3 ) 1-4 is hydrogen.
  • at least one R 13 in (Xaa 3 ) 1-4 is methyl.
  • at least one R 14 in (Xaa 3 ) 1-4 is -(CH 2 ) 2 [0(CH 2 ) 2 ] 1-6 - (e.g. when Xaa 3 is a residue of Amino-dPEGTM 4 -acid or Amino-dPEGTM 6 -acid).
  • one or more R x comprises a radiometal chelator optionally bound by a radiometal.
  • the radiometal chelator may be any radiometal chelator suitable for binding to the radiometal and which is functionalized for attachment to an amino group.
  • Many suitable radiometal chelators are known, e.g. as summarized in Price and Orvig, Chem. Soc. Rev., 2014, 43, 260-290, which is incorporated by reference in its entirety.
  • Radioisotope chelators include chelators selected from the group consisting of: DOTA and derivatives; DOTAGA; NOTA; NODAGA; NODASA; CB-D02A; 3p-C-DEPA; TCMC; D03A; DTPA and DTPA analogues optionally selected from CHX-A”-DTPA and 1 B4M-DTPA; TETA; NOPO; Me-3,2-HOPO; CB-TE1A1 P; CB-TE2P; MM-TE2A; DM-TE2A; sarcophagine and sarcophagine derivatives optionally selected from SarAr, SarAr-NCS, diamSar, AmBaSar, and BaBaSar; TRAP; AAZTA; DATA and DATA derivatives; H2 - macropa or a derivative thereof; H 2 dedpa, H 4 octapa, H 4 py4pa, H 4 Pypa, H 2 aza
  • R x comprises a radioisotope chelator selected from those listed above or in Table 2, or is any other radioisotope chelator.
  • R x comprises a radioisotope chelator selected from those listed above or in Table 2, or is any other radioisotope chelator.
  • One skilled in the art could replace any of the chelators listed herein with another chelator.
  • the radioisotope chelator is conjugated with a radioisotope.
  • the conjugated radioisotope may be, without limitation, 68 Ga, 61 Cu, 64 Cu, 67 Ga, 99m Tc, 111 In, 44 Sc, 86 Y, 89 Zr, 9 0 Nb, 177 Lu, 117m Sn, 165 Er, 90 Y, 227 Th, 225 Ac, 213 Bi, 212 Bi, 211 As, 203 Pb, 212 Pb, 47 Sc, 166 Ho, 188 Re, 186 Re, 1 49 Pm , 159 Gd, 105 Rh, 109 Pd, 198 Au, 199 Au, 175 Yb, 142 Pr, 1 14m ln, , and the like.
  • the chelator is a chelator from Table 2 and the conjugated radioisotope is a radioisotope indicated in Table 2 as a binder of the chelator.
  • the radioisotope chelator is not conjugated to a radioisotope.
  • the chelator is: DOTA or a derivative thereof, conjugated with
  • the chelator is TETA (1 ,4,8, 1 1-tetraazacyclotetradecane- 1 ,4,8, 1 1 -tetraacetic acid) , SarAr (1 -N-(4-Aminobenzyl)-3,6, 10,13,16,19-hexaazabicyclo[6.6.6]-eicosane- 1 , 8-diamine), NOTA (1 ,4,7-triazacyclononane-1 ,4,7-triacetic acid), TRAP (1 ,4,7-triazacyclononane- 1 ,4,7-tris[methyl(2-carboxyethyl)phosphinic acid), HBED (N,N0-bis(2-hydroxybenzyl)-ethylenediamine- N,NO-diacetic acid), 2,3-HOPO (3-hydroxypyridin-2-one), PCTA (3,6,9, 15-tetraazabicyclo[9.3.1]- pentadeca-1 (15), 1
  • R x may comprise a chelator for radiolabelling with 99m Tc, 94m Tc, 186 Re, or 1 88 Re, such as mercaptoacetyl, hydrazinonicotinamide, dimercaptosuccinic acid, 1 ,2-ethylenediylbis-L- cysteine diethyl ester, methylenediphosphonate, hexamethylpropyleneamineoxime and hexakis(methoxy isobutyl isonitrile, and the like.
  • a chelator for radiolabelling with 99m Tc, 94m Tc, 186 Re, or 1 88 Re such as mercaptoacetyl, hydrazinonicotinamide, dimercaptosuccinic acid, 1 ,2-ethylenediylbis-L- cysteine diethyl ester, methylenediphosphonate, hexamethylpropyleneamineoxime and hexakis(methoxy isobuty
  • one or more R x comprises a chelator, wherein the chelator is mercaptoacetyl, hydrazinonicotinamide, dimercaptosuccinic acid, 1 ,2- ethylenediylbis-L-cysteine diethyl ester, methylenediphosphonate, hexamethylpropyleneamineoxime or hexakis(methoxy isobutyl isonitrile).
  • the chelator is bound by a radioisotope.
  • the radioisotope is 99m Tc, 94m Tc, 186 Re, or 188 Re.
  • One or more R x may comprise a chelator that can bind 18 F-aluminum fluoride ([ 18 F]AIF), such as 1 ,4, 7-triazacyclononane-1 ,4-diacetate (NODA) and the like.
  • 18 F]AIF 18 F-aluminum fluoride
  • NODA 7-triazacyclononane-1 ,4-diacetate
  • the chelator is NODA.
  • the chelator is bound by [ 18 F]AIF.
  • One or more R x may comprise a chelator that can bind 72 As or 77 As, such as a trithiol chelate and the like.
  • the chelator is a trithiol chelate.
  • the chelator is conjugated to 72 As.
  • the chelator is conjugated to 77 As.
  • One or more R x may comprise an aryl group substituted with a radioisotope.
  • one or more R x is , wherein A, B, C, D and E are independently
  • R 15 is a radiohalogen. In some embodiments, one or more R x is .
  • one or more R x is . In some embodiments, one or more
  • R x is In some embodiments, one or more R x is . In some embodiments, one or more R x is . In some embodiments, one or more R x is . In some
  • one or more R x is . In some embodiments, one or more R x is . In some embodiments, one or more R x is . In some embodiments, one or more R x is . In some of these embodiments, R 15 is independently 211 At, 131 l, 124 l, 123 l, 77 Bror 18 F. In some of these embodiments, R 15 is
  • one or more R x may comprise a prosthetic group containing a trifluoroborate (BF 3 ), capable of 18 F/ 19 F exchange radiolabeling.
  • BF 3 trifluoroborate
  • one or more R x may comprise a prosthetic group containing a trifluoroborate (BF 3 ), capable of 18 F/ 19 F exchange radiolabeling.
  • one or more R x may comprise a prosthetic group containing a trifluoroborate (BF 3 ), capable of 18 F/ 19 F exchange radiolabeling.
  • BF 3 trifluoroborate
  • R 16 R 17 BF 3 may be R 16 R 17 BF 3 , wherein each R 16 is independently and R 18 is absent, .
  • Each -R 17 BF 3 may independently be selected from one or a
  • R 19 and R 20 are independently C 1 -C 5 linear or branched alkyl groups.
  • the R in the pyridine substituted with -OR, -SR, -NR-, -NHR or -NR2 groups is C 1 -C 5 branched or linear alkyl.
  • one or more -R 17 BF 3 is independently selected from one or a combination of those listed in Table 3.
  • one or more -R 17 BF 3 is independently selected from one or a combination of those listed in Table 4.
  • one fluorine is 18 F. In some embodiments, all three fluorines are 19 F.
  • R 17 BF 3 may form
  • R when present in the pyridine substituted -OR, -SR, -NR-, -NFIR or -NR 2 is a branched or linear C 1 - C 5 alkyl.
  • R is a branched or linear C 1 -C 5 saturated alkyl.
  • R is methyl.
  • R is ethyl.
  • R is propyl.
  • R is isopropyl.
  • R is n-butyl.
  • one fluorine is 1 8 F. In some embodiments, all three fluorines are 19 F.
  • -NR 2 is branched or linear C 1 -C 5 alkyl.
  • R is a branched or linear C 1 -C 5 saturated alkyl.
  • R is methyl.
  • R is ethyl.
  • R is propyl.
  • R is isopropyl.
  • R is n-butyl.
  • one or more -R 17 BF 3 is .
  • one fluorine is 18 F.
  • all three fluorines are 19 F.
  • one or more -R 17 BF 3 is . In some embodiments,
  • R 19 is methyl. In some embodiments, R 19 is ethyl. In some embodiments, R 19 is propyl. In some embodiments, R 19 is isopropyl. In some embodiments, R 19 is butyl. In some embodiments, R 19 is n- butyl. In some embodiments, R 19 is pentyl. In some embodiments, R 20 is methyl. In some embodiments, R 20 is ethyl. In some embodiments, R 20 is propyl. In some embodiments, R 20 is is isopropyl. In some embodiments, R 20 is butyl. In some embodiments, R 20 is n-butyl. In some embodiments, R 20 is pentyl. In some embodiments, R 19 and R 20 are both methyl. In some embodiments, one fluorine is 18 F. In some embodiments, all three fluorines are 19 F.
  • one or more R x may comprise a prosthetic group containing a silicon-fluorine-acceptor moiety.
  • the fluorine of the silicon-fluorine acceptor moiety is 18 F.
  • the prosthetic groups containing a silicon-fluorine-acceptor moiety may be independently
  • R 21 and R 22 are independently a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 10 alkyl, alkenyl or alkynyl group.
  • R 21 and R 22 are independently selected from the group consisting of phenyl, tert-butyl, sec-propyl or
  • the prosthetic group is . In some embodiments, the
  • the prosthetic group is . In some embodiments, the prosthetic group is
  • the prosthetic group is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-oxide-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • one or more R x comprise a prosthetic group containing a fluorophosphate. In some embodiments, one or more R x comprise a prosthetic group containing a fluorosulfate. In some embodiments, one or more R x comprise a prosthetic group containing a sulfonylfluoride. Such prosthetic groups are well known and are commercially available, and are facile to attach (e.g. via an amide linkage).
  • the fluorine atom in the fluorophosphate, fluorosulfate or sulfonylfuloride is 18 F. In some embodiments, the fluorine atom in the fluorophosphate, fluorosulfate or sulfonylfuloride is 19 F.
  • R 7 comprises two R x groups
  • R 7 has only a single radioactive atom.
  • one R x group may be 18 F labeled and the other R x group may comprise only 19 F or the other R x group may comprise a chelator that is not chelated with a radiometal or is chelated with a metal that is not a radioisotope .
  • one R x group may comprise an aryl substituted with a radioisotope and the other R x group may comprise only 19 F or the other R x group may comprise a chelator that is not chelated with a radiometal or is chelated with a metal that is not a radioisotope.
  • one R x group may comprise a chelator conjugated with a radioisotope and the other R x group may comprise only 19 F.
  • R 7 comprises a first R x group and a second R x group, wherein the first R x group is a radiometal chelator optionally bound by a radiometal and the second R x group is a prosthetic group containing a trifluoroborate.
  • R 7 comprises a first R x group and a second R x group, wherein the first R x group is a radiometal chelator optionally bound by a radiometal and the second R x group is a prosthetic group containing a trifluoroborate.
  • the compound is conjugated with a radioisotope for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging of PSMA expressing tumors, wherein the compound is conjugated with a radioisotope that is a positron emitter or a gamma emitter.
  • a radioisotope for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging of PSMA expressing tumors
  • SPECT single photon emission computed tomography
  • the positron or gamma emitting radioisotope is 68 Ga, 67 Ga, 61 Cu, 64 Cu, 99m Tc, 110m ln, 111 ln, 44 Sc, 86 Y, 89 Zr, 90 Nb, 18 F, 131 l, 123 l, 124 l and 72 As.
  • the compound is conjugated with a radioisotope that is used for therapy of PSMA-expressing tumors.
  • a radioisotope that is used for therapy of PSMA-expressing tumors.
  • the compound may be HTK03149 or a salt or solvate thereof, optionally conjugated with a radiometal.
  • the radiometal is 177 Lu, 111 In, 213 Bi, 68 Ga, 67 Ga, 203 Pb, 212 Pb, 44 Sc, 47 Sc, 90 Y, 86 Y, 225 Ac, 117m Sn, 153 Sm, 149 Tb, 161 Tb, 165 Er, 224 Ra, 212 Bi, 227 Th, 223 Ra, 64 Cu or 67 Cu.
  • the radiometal is 68 Ga.
  • the compound may be HTK03169, HTK03161 , HTK03177, HTK03187, HTK03153, HTK03170, HTK04053, HTK03189A, HTK03189B, HTK04018, HTK04033, HTK04040, HTK04036, HTK04037, HTK04041 , HTK04028, HTK04048, HTK04050, HTK03162, or HTK04055, or a salt or solvate thereof, optionally conjugated with a radiometal.
  • the radiometal is 177 Lu, 111 In, 213 Bi, 68 Ga, 67 Ga, 203 Pb, 212 Pb, 44 Sc, 47 Sc, 90 Y, 86 Y, 225 Ac, 117m Sn, 153 Sm, 149 Tb, 161 Tb, 165 Er, 224 Ra, 212 Bi, 227 Th, 223 Ra, 64 Cu or 67 Cu.
  • the radiometal is 68 Ga.
  • the radiometal is 177 Lu.
  • the radiolabeling group comprises or is conjugated to a diagnostic radioisotope
  • use of certain embodiments of the compound for preparation of a radiolabelled tracer for imaging PSMA-expressing tissues in a subject there is disclosed use of certain embodiments of the compound for preparation of a radiolabelled tracer for imaging PSMA-expressing tissues in a subject.
  • the method comprises: administering to the subject a composition comprising certain embodiments of the compound and a pharmaceutically acceptable excipient; and imaging tissue of the subject, e.g. using PET or SPECT.
  • tissue is a diseased tissue (e.g. a PSMA-expressing cancer)
  • PSMA-targeted treatment may then be selected for treating the subject.
  • the radiolabeling group comprises a therapeutic radioisotope
  • the compound for the treatment of PSMA-expressing conditions or diseases (e.g. cancer and the like) in a subject.
  • PSMA-expressing conditions or diseases e.g. cancer and the like
  • the method comprises: administering to the subject a composition comprising the compound and a pharmaceutically acceptable excipient.
  • the disease may be a PSMA-expressing cancer.
  • PSMA expression has been detected in various cancers (e.g. Rowe et al., 2015, Annals of Nuclear Medicine 29:877-882; Sathekge et al., 2015, EurJ Nucl Med Mol Imaging 42: 1482-1483; Verburg et al., 2015, Eur J Nucl Med Mol Imaging 42: 1622-1623; and Pyka et al., J Nucl Med November 19, 2015 jnumed.115.164442).
  • the PSMA-expressing cancer may be prostate cancer, renal cancer, breast cancer, thyroid cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, lung cancer, liver cancer, brain tumor, melanoma, neuroendocrine tumor, ovarian cancer or sarcoma.
  • the cancer is prostate cancer.
  • R 0 is S or O
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H,-PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF-, - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 -, -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 - -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 -, -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 0CH 2 -,-CH 2 SCH 2 -, -CHFCH 2 CH 2 -,
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -Se-, -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , -C(O)-
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl;
  • R 6 is hydrogen or methyl or ethyl
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; at least one R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkyn
  • R 23 is an optionally substituted C4-C16 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, NH 2 , N0 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • halogen OMe, SMe, NH 2 , NO 2 , CN, OH, or additional endocyclic ring nitrogen atoms;
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 28 is an albumin binder
  • Xaa 2 and Xaa 3 when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 13 is independently hydrogen or methyl, and wherein each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a metal; an aryl or heteroaryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluor
  • variables R 0 , R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 may be any such definition defined for Formula II.
  • X CH or N
  • Y NH, S or O
  • any of these triaryl/heteroaryl groups is modified optionally with one, more than one, or a combination of halogen, OMe, SMe, NH 2 , NO 2 , CN, OH, or one or more additional endocyclic ring nitrogen atoms.
  • R 0 is S or O
  • R 1a is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , -OPO 3 H 2 , -OSO 3 H, -B(OH) 2 , or
  • R 1b is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 1c is -CO 2 H, -SO 2 H, -SO 3 H -PO 2 H, -PO 3 H 2 , -B(OH) 2 , or
  • R 2 is -CH 2 -, -CH(OH)-, -CHF-, -CF 2 - -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH(OH)-, -CH 2 CHF- - CHFCH 2 -, -CF 2 CH 2 -, -CH 2 CF 2 -, -CH(OH)CH 2 - -CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 - -CH 2 C(CH 3 ) 2 -, -CH 2 CH(OH)CH 2 - -CH 2 CHFCH 2 -, -(CH 2 ) 2 CH(OH)-, -(CH 2 ) 2 CHF-, -(CH 2 ) 3 -, - CH 2 OCH 2 - -CH 2 SCH 2 -, -CHFCH 2 CH 2 -, -CH(OH
  • R 3 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl or heteroalkenylenyl;
  • R 4 is -O-, -S-, -Se- -S(O)-, -S(O) 2 -, -NHC(O)-, -C(O)NH-, , , -C(O)- (NH) 2 -C(O)-, -OC(O)NH, -NHC(O)O-, -NHC(O)NH-, -OC(S)NH, -NHC(S)O-, -NHC(S)NH-, - NHC(O)C(O)NH-, -S-S-, -S-CH 2 -S- -NH-NH-C(O)-, -C(O)-NH-NH-,
  • R 5 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 30 alkylenyl, alkenylenyl or alkynylenyl, or is a linear or branched, cyclic or acyclic, and/or aromatic or non- aromatic X 2 -X 30 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl
  • R 6 is optionally in carbonyl, a phosphoryl or a sulfonyl group that is linked to the alpha-nitrogen in Xaa 1 to respectively give an amide, phosphoramidate/phosphonamidate, or sulfonamide linkage; or alternatively is: -NHC(O)-, -(NH) 2 -C(O)-, -C(O)-(NH) 2 -C(O)-, -OC(O)-, -OC(S)-, -NHC(S)-, - NHC(O)C(O)-, -NH-NH-C(O)-, to enjoin the alpha-nitrogen in Xaa 1 .
  • Xaa 1 is an amino acid of formula -N(R 8 )R 9 C(O)-, wherein each R 8 is independently hydrogen or methyl, and wherein each R 9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or
  • R 9 or R 5 is -(CH 2 ) 0-3 CH(R 10 )(CH 2 ) 0-3 -, wherein R 10 is: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 2 -C 19 alkyl, alkenyl or alkynyl; a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 19 heteroalkyl, heteroalkenyl or heteroalkynyl having only 1-3 heteroatoms;
  • R 23 is an optionally substituted C 4 -C 16 aromatic ring or partially or fully aromatic fused ring system, wherein 0-3 carbons in the aromatic ring or the partially or fully aromatic fused ring system are replaced with N, S and/or O heteroatoms, and wherein the optional substitutions are selected from OH, NH 2 , NO 2 , halogen, C 1 -C 6 alkyl, and/or C 1 -C 6 alkoxyl groups; or selected from:
  • halogen OMe, SMe, NH 2 , NO 2 , CN, OH, or additional endocyclic ring nitrogen atoms;
  • R 7 is R x -(Xaa 2 ) 0-4 -,
  • R 28 is an albumin binder
  • Xaa 2 and Xaa 3 when present, are independently -N(R 13 )R 14 C(O)-, wherein each R 1 3 is
  • each R 14 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C 1 -C 20 alkylenyl, alkenylenyl or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic X 2 -X 20 heteroalkylenyl, heteroalkenylenyl or heteroalkynylenyl; and each R x is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a metal; an aryl or heteroaryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety, a fluorophosphate, a fluorosulfate, or a sulfonylfluoride.
  • variables R 0 , R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , or any variable defined in the definitions for the foregoing variables or for variables R 6 or R 7 may be any such definition defined for Formula II.
  • peptides which may be synthesized by any of a variety of methods established in the art. This includes but is not limited to liquid-phase as well as solid-phase peptide synthesis using methods employing 9-fluorenylmethoxycarbonyl (Fmoc) and/or t-butyloxycarbonyl (Boc) chemistries, and/or other synthetic approaches.
  • Fmoc 9-fluorenylmethoxycarbonyl
  • Boc t-butyloxycarbonyl
  • peptides may be synthesized by sequential incorporation of the amino acid residues of interest one at a time.
  • peptide synthesis is typically initiated by attaching the C- terminal amino acid of the peptide of interest to a suitable resin.
  • suitable protecting groups Prior to this, reactive side chain and alpha amino groups of the amino acids are protected from reaction by suitable protecting groups, allowing only the alpha carboxyl group to react with a functional group such as an amine group, a hydroxyl group, or an alkyl halide group on the solid support.
  • the protecting group on the side chain and/or the alpha amino group of the amino acid is selectively removed, allowing the coupling of the next amino acid of interest. This process is repeated until the desired peptide is fully synthesized, at which point the peptide can be cleaved from the support and purified.
  • a non-limiting example of an instrument for solid-phase peptide synthesis is the Aapptec Endeavor 90 peptide synthesizer.
  • Fmoc protecting groups may be removed from the amino acid on the solid support, e.g. under mild basic conditions, such as piperidine (20-50% v/v) in DMF.
  • the amino acid to be added must also have been activated for coupling (e.g. at the alpha carboxylate).
  • Non-limiting examples of activating reagents include without limitation 2-(1 H-benzotriazol- 1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazol-1-yl)-1,1,3,3- tetramethyluronium tetrafluoroborate (TBTU), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3- tetramethyluronium hexafluorophosphate (HATU), benzotriazole-1-yl-oxy- tris(dimethylamino)phosphoniumhexafluorophosphate (BOP), benzotriazole-1-yl-oxy- tris(pyrrolidino)phosphoniumhexafluorophosphate (PyBOP).
  • HBTU 2-(1 H-benzotriazol- 1-yl)-1,1,3,3-tetramethyluronium hexa
  • Racemization is minimized by using triazoles, such as 1-hydroxy-benzotriazole (HOBt) and 1-hydroxy-7-aza-benzotriazole (HOAt). Coupling may be performed in the presence of a suitable base, such as N,N-diisopropylethylamine (DIPEA/DIEA) and the like. For long peptides or if desired, peptide synthesis and ligation may be used. [00176] Apart from forming typical peptide bonds to elongate a peptide, peptides may be elongated in a branched fashion by attaching to side chain functional groups (e.g.
  • carboxylic acid groups or amino groups either: side chain to side chain; or side chain to backbone amino or carboxylate. Coupling to amino acid side chains may be performed by any known method, and may be performed on-resin or off-resin. Non-limiting examples include: forming an amide between an amino acid side chain containing a carboxyl group (e.g. Asp, D-Asp, Glu, D-Glu, and the like) and an amino acid side chain containing an amino group (e.g.
  • Non-limiting examples of selectively removable protecting groups include 2-phenylisopropyl esters (O-2-PhiPr) (e.g. on Asp/Glu) as well as 4-methyltrityl (Mtt), allyloxycarbonyl (alloc), 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene))ethyl (Dde), and 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) (e.g. on Lys/Orn/Dab/Dap).
  • 2-phenylisopropyl esters O-2-PhiPr
  • Mtt 4-methyltrityl
  • alloc allyloxycarbonyl
  • alloc 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene))ethyl
  • ivDde 1-
  • O-2-PhiPr and Mtt protecting groups can be selectively deprotected under mild acidic conditions, such as 2.5% trifluoroacetic acid (TFA) in DCM.
  • Alloc protecting groups can be selectively deprotected using tetrakis(triphenylphosphine)palladium(0) and phenyl silane in DCM.
  • Dde and ivDde protecting groups can be selectively deprotected using 2-5% of hydrazine in DMF.
  • Deprotected side chains of Asp/Glu (L- or D-forms) and Lys/Orn/Dab/Dap (L- or D-forms) can then be coupled, e.g. by using the coupling reaction conditions described above.
  • Peptide backbone amides may be N-methylated (i.e. alpha amino methylated). This may be achieved by directly using Fmoc-N-methylated amino acids during peptide synthesis. Alternatively, N-methylation under Mitsunobu conditions may be performed. First, a free primary amine group is protected using a solution of 4-nitrobenzenesulfonyl chloride (Ns-CI) and 2,4,6-trimethylpyridine (collidine) in NMP. N-methylation may then be achieved in the presence of triphenylphosphine, diisopropyl azodicarboxylate (DIAD) and methanol.
  • Ns-CI 4-nitrobenzenesulfonyl chloride
  • DIAD diisopropyl azodicarboxylate
  • N-deprotection may be performed using mercaptoethanol and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in NMP.
  • DBU 1 ,8-diazabicyclo[5.4.0]undec-7-ene
  • HATU, HOAt and DIEA may be used for coupling protected amino acids to N-methylated alpha amino groups.
  • the PSMA-binding moiety (e.g. Lys-ureido-Aad, and the like) may be constructed on solid phase via the formation of a ureido linkage between the amino groups of two amino acids. This can be done by attaching an Fmoc-protecting amino acid (for example Fmoc-Lys(ivDde)-OH) to Wang resin using standard activation/coupling strategy (for example, Fmoc- protected amino acid (4 eq.), HATU (4 eq.) and N, -diisopropylethylamine (7 eq.) in N,N-dimethylformamide).
  • Fmoc-protecting amino acid for example Fmoc-Lys(ivDde)-OH
  • the Fmoc-protecting group is then removed by 20% piperidine in N,N-dimethylformamide.
  • the activation and conversion of an amino group to an isocyanate group can be achieved by reacting the amino group with phosgene or triphosgene.
  • the side chain functional group of the amino acid for example ivDde on Lys
  • the linker, albumin-binding motif, and/or radiolabeling group e.g. radiometal chelator and the like
  • thioether (-S-) and ether (-O-) linkages can be achieved either on solid phase or in solution phase.
  • the formation of thioether (-S-) linkage can be achieved by coupling between a thiol-containing compound (such as the thiol group on cysteine side chain) and an alkyl halide (such as 3-(Fmoc-amino)propyl bromide and the like) in an appropriate solvent (such as N,N-dimethylformamide and the like) in the presence of base (such as N,N- diisopropylethylamine and the like).
  • a thiol-containing compound such as the thiol group on cysteine side chain
  • an alkyl halide such as 3-(Fmoc-amino)propyl bromide and the like
  • an appropriate solvent such as N,N-dimethylformamide and the like
  • base such as N,N- diisopropylethylamine and the like
  • an ether (-O-) linkage can be achieved via the Mitsunobu reaction between an alcohol (such as the hydroxyl group on the side chain of serine or threonine, for example) and a phenol group (such as the side chain of tyrosine, for example) in the presence of triphenylphosphine and diisopropyl azidicarboxylate (DIAD) in an aprotic solvent (such as 1 ,4-dioxane and the like).
  • the reactants used are preferably in equivalent molar ratio (1 to 1), and the desired products can be purified by flash column chromatography or high performance liquid chromatography (HPLC).
  • the reactions are carried out on solid phase, meaning one reactant has been attached to a solid phase, then the other reactant is normally used in excess amount (3 3 equivalents of the reactant attached to the solid phase).
  • the excess unreacted reactant and reagents can be removed by sequentially washing the solid phase (resin) using a combination of solvents, such as N,N-dimethylformamide, methanol and dichloromethane, for example.
  • Non-peptide moieties e.g. radiolabeling groups, albumin-binding groups and/or linkers
  • a bifunctional chelator such as 1 ,4,7, 10-tetraazacyclododecane-1 ,4,7, 10-tetraacetic acid (DOTA) tris(tert- butyl ester) may be activated in the presence of N-hydroxysuccinimide (NHS) and N,N'- dicyclohexylcarbodiimide (DCC) for coupling to a peptide.
  • N-hydroxysuccinimide (NHS) and N,N'- dicyclohexylcarbodiimide (DCC) for coupling to a peptide.
  • a non-peptide moiety may be incorporated into the compound via a copper-catalyzed click reaction under either liquid or solid phase conditions. Copper-catalyzed click reactions are well established in the art.
  • 2-azidoacetic acid is first activated by NHS and DCC and coupled to a peptide. Then, an alkyne-containing non- peptide moiety may be clicked to the azide-containing peptide in the presence of Cu 2+ and sodium ascorbate in water and organic solvent, such as acetonitrile (ACN) and DMF and the like.
  • organic solvent such as acetonitrile (ACN) and DMF and the like.
  • radiometal chelators The synthesis of radiometal chelators is well-known and many chelators are commercially available (e.g. from Sigma-AldrichTM/Milipore SigmaTM and others). Protocols for conjugation of radiometals to the chelators are also well known (e.g. see Example 1 , below).
  • the synthesis of the silicon-fluorine-acceptor moieties can be achieved following previously reported procedures (e.g. Bernard-Gauthier et al. Biomed Res Int. 2014 2014:454503; Kostikov et al. Nature Protocols 2012 7: 1956-1963; Kostikov et al. Bioconjug Chem. 2012 18:23:106-1 14; each of which is incorporated by reference in its entirety).
  • the synthesis or acquisition of radioisotope-substituted aryl groups is likewise facile.
  • the BF 3 -containing motif can be coupled to the linker via click chemistry by forming a 1 ,2,3-triazole ring between a BF 3 -containg azido (or alkynyl) group and an alkynyl (or azido) group on the linker, or by forming an amide linkage between a BF 3 -containg carboxylate and an amino group on the linker.
  • a boronic acid ester-containing azide, alkyne or carboxylate is first prepared following by the conversion of the boronic acid ester to BF 3 in a mixture of HCI, DMF and KHF 2 .
  • the boronic acid ester-containing azide, alkyne or carboxylate can be prepared by coupling boronic acid ester-containing alkyl halide (such as iodomethylboronic acid pinacol ester) with an amine-containing azide, alkyne or carboxylate (such as N, N-dimethylpropargylamine).
  • boronic acid ester-containing alkyl halide such as iodomethylboronic acid pinacol ester
  • an amine-containing azide, alkyne or carboxylate such as N, N-dimethylpropargylamine.
  • the boronic acid ester can be prepared via Suzuki coupling using aryl halide (iodine or bromide) and bis(pinacolato)diboron.
  • the desired peptide may be cleaved from the solid support using suitable reagents, such as TFA, tri-isopropylsilane (TIS) and water.
  • suitable reagents such as TFA, tri-isopropylsilane (TIS) and water.
  • Side chain protecting groups such as Boc, pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), trityl (Trt) and tert-butyl (tBu) are simultaneously removed (i.e. deprotection).
  • the crude peptide may be precipitated and collected from the solution by adding cold ether followed by centrifugation.
  • Purification and characterization of the peptides may be performed by standard separation techniques, such as high performance liquid chromatography (HPLC) based on the size, charge and polarity of the peptides.
  • HPLC high performance liquid chromatography
  • the identity of the purified peptides may be confirmed by mass spectrometry or other similar approaches.
  • a synthetic scheme for HTK03149 and conjugation with 68 Ga is depicted in Figure 2 and is explained in further detail in Example 1 below. Examples of general synthetic schemes for additional compounds are shown in Figures 3 and 4. Synthesis and testing of exemplary compounds HTK03041 , HTK03169, HTK03161 , HTK03177, HTK03187, HTK03153, HTK03170, HTK04053, HTK03189 (A and B), HTK04018, HTK04033, HTK04040, HTK04036, HTK04037, HTK04041 , HTK04028, HTK04048, HTK04050, HTK03162, and HTK04055 are described in Example 2.
  • PSMA-targeted peptides were synthesized using a solid phase approach on an AAPPTec (Louisville, KY) Endeavor 90 peptide synthesizer. Purification of peptides was performed on an Agilent 1260 Infinity II Preparative System equipped with a model 1260 Infinity II preparative binary pump, a model 1260 Infinity variable wavelength detector (set at 220 nm), and a 1290 Infinity II preparative open-bed fraction collector.
  • the HPLC column used was a preparative column (Gemini, NX-C18, 5 m, 50 ⁇ 30 mm) purchased from Phenomenex.
  • the collected HPLC eluates containing the desired peptide were lyophilized using a Labconco (Kansas City, MO) FreeZone 4.5 Plus freeze-drier. Mass analyses were performed using an AB SCIEX (Framingham, MA) 4000 QTRAP mass spectrometer system with an ESI ion source. C18 Sep-Pak cartridges (1 cm 3 , 50 mg) were obtained from Waters (Milford, MA). 68 Ga was eluted from an iThemba Labs (Somerset West, South Africa) generator.
  • Radioactivity of 68 Ga-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC ® - 25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Perkin Elmer (Waltham, MA) Wizard2 2480 automatic gamma counter.
  • HTK03041 and HTK03149 are shown below, which only differ in that the former has a Glu residue in the PSMA binding moiety (Lys-ureido-Glu) whereas the latter has an Aad in the PSMA binding moiety (Lys-ureido-Aad) and therefore a side chain that is longer by one carbon:
  • the peptidomimetic PSMA-targeting Lys-ureido-Aad moiety was synthesized by solid-phase peptide chemistry.
  • Fmoc-Lys(ivDde)-Wang resin (0.05 mmol, 0.58 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 ⁇ 8 min).
  • Fmoc-Ala(9-Anth)-OH was then coupled to the side chain of Lys using Fmoc-protected amino acid (4 eq.), HATU (4 eq.), and N, -diisopropylethylamine (7 eq.). Afterwards, elongation was continued with the addition of Fmoc-tranexamic acid, and finally DOTA- tris(t-bu)ester (2-(4,7,10-tris(2-(t-butoxy)-2-oxoehtyl)-1 ,4,7,10)-tetraazacyclododecan-1-yl)acetic acid).
  • Ga-HTK03149 a solution of HTK03149 was incubated with GaCl 3 (5 eq.) in NaOAc buffer (0.1 M, 500 mL , pH 4.2) at 80 °C for 15 min. The reaction mixture was then purified by HPLC using the semi-preparative column, and the HPLC eluates containing the desired peptide were collected, pooled, and lyophilized. The HPLC conditions were 24% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 10.9 min. The yield of Ga-HTK03149 was 90.3%. ESI-MS: calculated [M+H] + for Ga-HTK03149 C 54 H 9 O 16 Ga 1173.4509; found [M+H] + 1173.5450.
  • LNCaP cell line was obtained from ATCC (LNCaP clone FGC, CRL-1740). It was established from a metastatic site of left supraclavicular lymph node of human prostatic adenocarcinoma. Cells were cultured in PRM1 1640 medium supplemented with 10 % FBS, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in a humidified incubator containing 5% CO 2 . Cells grown to 80-90% confluence were then washed with sterile phosphate-buffered saline (1 ⁇ PBS pH 7.4) and collected by trypsinization. The collected cells concentration was counted with a Hausser Scientific (Horsham, PA) Hemacytometer.
  • Imaging and biodistribution experiments were performed using NODSCID 1 L2RgKO male mice. Mice were anesthetized by inhalation with 2% isoflurane in oxygen, and implanted subcutaneously with 1 ⁇ 10 7 LNCaP cells behind left shoulder. Mice were imaged or used in biodisthbution studies when the tumor grew up to reach 5-8 mm in diameter during 5-6 weeks.
  • PET imaging experiments were conducted using Siemens Inveon micro PET/CT scanner. Each tumor bearing mouse was injected 6 - 8 MBq of Ga-68 labeled tracer through the tail vein under anesthesia (2% isoflurane in oxygen). The mice were allowed to recover and roam freely in their cage. After 50 min, the mice were sedated again with 2% isoflurane in oxygen inhalation and positioned in the scanner. A 10-min CT scan was conducted first for localization and attenuation correction after segmentation for reconstructing the PET images. Then, a 10-min static PET imaging was performed to determined uptake in tumor and other organs. The mice were kept warm by a heating pad during acquisition. For biodisthbution studies, the mice were injected with the radiotracer as described above.
  • mice was anesthetized with 2% isoflurane inhalation, and euthanized by CO 2 inhalation.
  • Blood was withdrawn immediately from the heart, and the organs/tissues of interest were collected.
  • the collected organs/tissues were weighed and counted using a Perkin Elmer (Waltham, MA) Wizard2 2480 gamma counter.
  • the uptake in each organ/tissue was normalized to the injected dose using a standard curve, and expressed as the percentage of the injected dose per gram of tissue (%lD/g).
  • Figure 5 shows images obtained at 1 and 3 hours following the intravenous injection of 68 Ga- HTK03149. The images show very high tumour accumulation (solid arrow) with minimal kidney accumulation (dotted arrow) and very low activity in other organs.
  • Tables 5A and 5B show biodisthbution data for HTK03149 at 1 hr and 3 hr post- injection, and Table 6 shows biodisthbution data for HTK03041 at 1 hr post-injection.
  • TABLE 5A Biodisthbution data and tumor-to-background contrast ratios of 68 Ga-labeled HTK03149 in mice bearing PSMA-expressing LNCAP cancer xenografts at 1 h post-injection.
  • TABLE 5B Biodistribution data and tumor-to-background contrast ratios of 68 Ga-labeled HTK03149 in mice bearing PSMA-expressing LNCAP cancer xenografts at 3h post-injection.
  • EXAMPLE 2 HTK03041 , HTK03169, HTK03161 , HTK03177, HTK03187, HTK03153, HTK03170, HTK04053, HTK03189 (A and B), HTK04018, HTK04033, HTK04040, HTK04036, HTK04037, HTK04041 , HTK04028, HTK04048, HTK04050, HTK03162, and HTK04055
  • PSMA-targeted peptides were synthesized using solid phase approach on an AAPPTec (Louisville, KY) Endeavor 90 peptide synthesizer. Purification and quality control of cold and radiolabeled peptides were performed on (1) Agilent HPLC systems equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector (set at 220 nm), and a Bioscan (Washington, DC) Nal scintillation detector. The operation of Agilent HPLC systems was controlled using the Agilent ChemStation software.
  • the HPLC columns used were a semi-preparative column (Luna C18, 5 m, 250 ⁇ 10 mm) and an analytical column (Luna C18, 5 m, 250 ⁇ 4.6 mm) purchased from Phenomenex (Torrance, CA); or (2) an Agilent 1260 Infinity II Preparative System equipped with a model 1260 Infinity II preparative binary pump, a model 1260 Infinity variable wavelength detector (set at 220 nm), and a 1290 Infinity II preparative open-bed fraction collector.
  • the HPLC column used was a preparative column (Gemini, NX-C18, 5 m, 50 ⁇ 30 mm) purchased from Phenomenex.
  • the collected HPLC eluates containing the desired peptide were lyophilized using a Labconco (Kansas City, MO) FreeZone 4.5 Plus freeze-drier. Mass analyses were performed using an AB SCIEX (Framingham, MA) 4000 QTRAP mass spectrometer system with an ESI ion source. C18 Sep-Pak cartridges (1 cm 3 , 50 mg) were obtained from Waters (Milford, MA).
  • Radioactivity of 68 Ga-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC ® -25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Perkin Elmer (Waltham, MA) Wizard22480 automatic gamma counter.
  • HTK03041 HTK03149, HTK03169, HTK03161 , HTK03177, HTK03187, HTK03153, HTK03170, HTK04053, HTK03189A, HTK03189B, HTK04018, HTK04033, HTK04040, HTK04036, HTK04037, HTK04041 , HTK04028, HTK04048, HTK04050, HTK03162, and HTK04055 are shown in Figure 6.
  • the peptidomimetic PSMA-targeting Aad-ureido-lysine moiety was synthesized by solid- phase peptide chemistry.
  • Fmoc-Lys(ivDde)-Wang resin (0.10 mmol, 0.58 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 ⁇ 8 min).
  • Fmoc-2-naphthylalanine (for HTK03169) or Fmoc-3-iodo-L- phenylalanine (for HTK04053) was then coupled to the side chain of Lys using Fmoc- protected amino acid (4 eq.), HATU (4 eq.), and DIEA (7 eq.). Afterwards, elongation was continued with the addition of Fmoc-tranexamic acid, and finally DOTA-tris(t-bu)ester (2-(4,7,10-tris(2-(t-butoxy)-2-oxoehtyl)-1 ,4,7,10)- tetraazacyclododecan-1-yl)acetic acid).
  • the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 trifluoroacetic acid (TFA)/triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the preparative or semi-preparative column. The eluates containing the desired peptide were collected and lyophilized. For HTK03169, the preparative HPLC condition was 20% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 9.0 min. The yield was 29.6%.
  • ESI-MS calculated [M+H] + for HTK03169 C 50 H 73 N 9 O 16 1056.5254; found [M+H] + 1056.5647.
  • the semi-preparative HPLC condition was 24% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 1 1.9 min. The yield was 47.6 %.
  • ESI-MS calculated [M+H] + for HTK04053 C 46 H 70 N 9 O 16 I 1132.4063; found [M+H] + 1132.5523.
  • Fmoc-Lys(ivDde)-Wang resin (0.1 mmol, 0.58 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 ⁇ 8 min).
  • Triphosgene (49.0 mg, 0.165 mmol) was dissolved in CH 2 CI 2 (5 mL), and the resulting solution was added dropwise to the reaction at -78 °C. The reaction was then allowed to warm to room temperature and stirred for 30 minutes to give a solution of the derivative. After which another 87.1 mL DIEA (0.5 mmole) was added, and then added to the lysine-immobilized resin and reacted for 16 h. After washing the resin with DMF, the ivDde-protecting group was removed with 2% hydrazine in DMF (5 ⁇ 5 min).
  • Fmoc-Ala(9-Anth)-OH was then coupled to the side chain of Lys using Fmoc-protected amino acid (4 eq.), HATU (4 eq.), and DIEA (7 eq.). Afterwards, elongation was continued with the addition of Fmoc-tranexamic acid, and finally DOTA-tris(t-bu)ester.
  • the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 trifluoroacetic acid (TFA)/triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the preparative or semi-preparative column. The eluates containing the desired peptide were collected and lyophilized. For HTK03161 , the preparative HPLC condition was 23% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 7.9 min.
  • the preparative HPLC condition was 24% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 8.2 min. The yield was 34.0%.
  • ESI-MS calculated [M+H] + for HTK03177 C 53 H 73 N 9 O 16 S 1124.4974; found [M+H] + 1124.4980.
  • the semi-preparative HPLC condition was 28% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.4 min. The yield was 30.3%.
  • ESI-MS calculated [M+H] + for HTK03189 C 55 H 77 N 9 O 16 1120.5567; found [M+H] + 1120.5865 for HTK03189A and 1120.5118 for HTK03189B.
  • HTK04018 the semi-preparative HPLC condition was 30% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.2 min.
  • ESI-MS calculated [M+H] + for HTK04018 C 53 H 73 N 9 O 18 S 1156.4873; found [M+H] + 1156.3678.
  • the preparative HPLC condition was 23% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 8.5 min. The yield was 45.7%.
  • ESI-MS calculated [M+H] + for HTK04033 C 53 H 72 N 9 O 16 F 1 110.5159; found [M+H] + 1 110.3887.
  • the preparative HPLC condition was 23% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 9.4 min. The yield was 33.3%.
  • ESI-MS calculated [M+H] + for HTK04040 C 53 H 72 N 9 O 16 F 11 10.5159; found [M+H] + 1 110.0578.
  • peptidomimetic PSMA-targeting Aad-ureido-lysine moiety was synthesized by solid- phase peptide chemistry.
  • Fmoc-Lys(ivDde)-Wang resin (0.10 mmol, 0.58 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 ⁇ 8 min).
  • the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 TFA/TIS for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the preparative or semi-preparative column. The eluates containing the desired peptide were collected and lyophilized.
  • the preparative HPLC condition was 23% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 9.7 min. The yield was 28.2%.
  • ESI-MS calculated [M+H] + for HTK04036 C 55 H 71 N 9 O 16 1114.5097; found [M+H] + 1114.3070.
  • the preparative HPLC condition was 23% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 1 1.6 min. The yield was 27.0%.
  • ESI-MS calculated [M+H] + for HTK04037 C 55 H 71 N 9 O 16 11 14.5097; found [M+H] + 1 114.3629.
  • peptidomimetic PSMA-targeting Aad-ureido-lysine moiety was synthesized by solid- phase peptide chemistry.
  • Fmoc-Lys(ivDde)-Wang resin (0.10 mmol, 0.58 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 ⁇ 8 min).
  • Fmoc-Ala(9-Anth)-OH was then coupled to the side chain of Lys followed by Fmoc- tranexamic acid, Fmoc-Lys(ivDde)-OH, and Fmoc-Gly-OH using Fmoc-based chemistry. All coupling were carried out in DMF using Fmoc-protected amino acid (4 eq.), HATU (4 eq.), and DIEA (7 eq.).
  • the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 TFA/TIS for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the preparative or semi-preparative column. The eluates containing the desired peptide were collected and lyophilized.
  • the preparative HPLC condition was 32% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 7.9 min.
  • the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 TFA/TIS for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the preparative or semi-preparative column. The eluates containing the desired peptide were collected and lyophilized.
  • the preparative HPLC condition was 28% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 14.8 min. The yield was 21.4 %.
  • ESI-MS calculated [M+H] + for HTK04028 C 72 H 100 N 12 O 21 1469.7204; found [M+H] + 1469.7000.
  • HTK04048 the semi-preparative HPLC condition was 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 1 1.7 min. The yield was 53.4 %.
  • ESI-MS calculated [M+H] + for HTK04048 C 72 H 100 N 12 O 20 S 1485.6976; found [M+H] + 1485.9910.
  • HTK04050 the semi-preparative H PLC condition was 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 11.4 min. The yield was 17.5 %.
  • ESI-MS calculated [M+H] + for HTK04050 C 72 H 99 N 12 O 20 F 1471.7161 ; found [M+H] + 1471.9511.
  • ESI-MS calculated [M+H] + for Ga- HTK03041 C 53 H 72 N 9 O 16 Ga 1159.4; found [M+H] + 1159.4.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 11.3 min. The yield was 37.4 %.
  • ESI-MS calculated [M+H] + for Ga-HTK03161 C 52 H 69 N 9 O 16 Ga 1145.4196; found [M+H] + 1 146.1355.
  • the semi-preparative HPLC condition was 25% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 14.1 min. The yield was 55.0 %.
  • ESI-MS calculated [M+H] + for Ga-HTK03169 C 50 H 70 N 9 O 16 Ga 1122.4275; found [M+H] + 1122.3041.
  • the semi-preparative HPLC condition was 32% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 7.8 min. The yield was 55.9 %.
  • ESI-MS calculated [M+H] + forGa-HTK03179 C 53 H 70 N 9 O 16 SGa 1190.3995; found [M+H] + 1190.3061.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.3 min. The yield was 52.8%.
  • ESI-MS calculated [M+H] + for Ga-HTK03187 C 53 H 70 N 9 O 17 Ga 1174.4224; found [M+H] + 1174.3425.
  • Ga-HTK03189A the semi-preparative HPLC condition was 30% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.0 min. The yield was 52.6 %.
  • ESI-MS calculated [M+H]+ for Ga- HTK03189A C55H74N9O16Ga 1186.4588; found [M+H]+ 1 186.4164.
  • the semi- preparative HPLC condition was 30% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.9 min. The yield was 42.1 %.
  • ESI-MS calculated [M+H]+ for Ga-HTK03189B C55H74N9O16Ga 1186.4588; found [M+H]+ 1 186.3279.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.3 min. The yield was 59.5 %.
  • ESI-MS calculated [M+H]+ for Ga-HTK04033 C53H 70N9O16FGa 1 177.4259; found [M+H]+ 1 178.4800.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.1 min. The yield was 61.3 %.
  • ESI-MS calculated [M+H]+ for Ga-HTK04036 C55H69N9O16Ga 1181.4196; found [M+H]+ 1 181.4720.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 15.6 min. The yield was 54.2%.
  • ESI-MS calculated [M+H]+ for Ga-HTK04037 C55H69N9O16Ga 1181.4196; found [M+H]+ 1 180.5278.
  • the semi-preparative HPLC condition was 30% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.2 min. The yield was 46.5%.
  • ESI-MS calculated [M+H]+ for Ga-HTK04040 C53H70N9O16FGa 1 177.4259; found [M+H]+ 1 176.7043.
  • the semi-preparative HPLC condition was 29% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 14.4 min. The yield was 55.2%.
  • ESI-MS calculated [M+H]+ for Ga-HTK04041 C53H 65N9O16Ga 1153.3883; found [M+H]+ 1 153.5379.
  • the semi-preparative HPLC condition was 25% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 12.4 min. The yield was 74.7%.
  • ESI-MS calculated [M+H]+ for Ga-HTK04053 C46H68N9O16Ga 1199.3163; found [M+H]+ 1199.5712.
  • Lu- HTK03149 The retention time was 8.4 min.
  • the yield of Lu- HTK03149 was 91.3 %.
  • ESI-MS calculated [M+H] + for Lu-HTK03149 C 54 H 74 N 9 O 16 LU 1173.4509; found [M+H] + 1173.5450.
  • the HPLC condition was 39% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min.
  • the retention time was 8.1 min.
  • the yield of Lu-HTK03153 was 62.5 %.
  • ESI-MS calculated [M+H] + for Lu-HTK03153 C 72 H 96 N 12 O 1 9 CILU 1643.6089; found [M+H] + 1643.9000.
  • Lu-HTK03170 the HPLC condition was 34% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 15.4 min. The yield of Lu-HTK03170 was 94.7 %.
  • ESI-MS calculated [M+H] + for Lu-HTK03170 C 73 H 99 N 12 O 20 Lu 1639.6585; found [M+H] + 1639.6933.
  • Lu- HTK04028 the HPLC condition was 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 1 1.5 min. The yield of Lu-HTK04028 was 29.4 %.
  • ESI-MS calculated [M+H] + for Lu-HTK04028 C 72 H 97 N 12 O 21 Lu 1641.6377; found [M+H] + 1641.7775.
  • the HPLC condition was 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.9 min. The yield of Lu-HTK04048 was 70.2 %.
  • ESI-MS calculated [M+H] + for Lu- HTK04048 C 72 H 97 N 12 O 20 SLu 1657.6149; found [M+H] + 1657.8672.
  • Lu-HTK04050 the HPLC condition was 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.2 min. The yield of Lu-HTK04050 was 44.9 %.
  • ESI-MS calculated [M+H] + for Lu-HTK04050 C 72 H 96 N 12 O 20 FLu 1643.6334; found [M+H] + 1644.7152.
  • HTK03156 and HTK04039 for the synthesis of HTK03162 and HTK04055, respectively, were synthesized by solid-phase methods.
  • the synthesis procedures for the preparation of their core structures were the same as the syntheses of HTK03149 (for HTK03156) and HTK03187 (for HTK04039).
  • Fmoc-tranexamic acid After coupling Fmoc-tranexamic acid, elongation was continued with the addition of Fmoc-Lys(Fmoc)-OH.
  • the couplings were carried out in DMF using Fmoc-protected amino acid (4 equivalents), HATU (4 equivalents) and DIEA (7 equivalents).
  • Fmoc-Aad(OtBu)-OH was then coupled to both side-chain and N- terminus of Lys.
  • the couplings were carried out in DMF using Fmoc-protected amino acid (5 equivalents), HATU (5 equivalentsand DIEA (9 equivalents).
  • 2-Azidoacetic acid (5 equivalents) was coupled to the N -terminus with DIEA (5 equivalents) and N -hydroxysuccinimide (6 equivalents) to give the di-azide-containing intermediates.
  • the peptide was deprotected and simultaneously cleaved from the resin by treating with 95/5 TFA/TIS for 2 h at room temperature.
  • the peptide was precipitated by the addition of cold diethyl ether to the TFA solution.
  • the crude peptide was purified by HPLC using the preparative column. The eluates containing the desired peptide were collected, pooled, and lyophilized.
  • the preparative HPLC condition was 34% acetonitrile in water with 0.1 % TFA at a flow rate of 30 mL/min. The retention time was 4.8 min, and the yield of the precursor was 39%.
  • ESI-MS calculated [M+H] + C 60 H 82 N 15 O 18 1300.5962; found [M+H] + 1300.6369.
  • HTK03162 To synthesize HTK03162, the di-azide-containing intermediate HTK03156 (7.4 mg, 5.7 pmol), N -propargyl-N,N -dimethylammoniomethyl-trifluoroborate (4.7 mg, 28.5 pmol, 5eq) were dissolved in 300 mL actonirile, and then adjusting the solution to base condition (pH ⁇ 8) by 1 M K 2 CO 3 . A solution of 1 M CuSO 4 (28.5 mL, 5eq), and 1 M sodium ascorbate (57 mL, 10eq) was then added, and the reaction mixture was stirred at room temperature for 18 h.
  • reaction mixture was purified by HPLC using the semi-preparative column eluted with 36% acetonitrile acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 8.0 min, and the yield of the HTK03162 was 70.7 %.
  • ESI-MS calculated [M+H] + C 72 H 104 B 2 F 6 N 17 O 18 1630.7836; found [M+H] + 1630.8000.
  • HTK04055 To synthesize HTK04055, the di-azide-containing intermediate HTK04039 (2.0 mg, 1.5 pmol), N -propargyl-N, -dimethylammoniomethyl-trifluoroborate (1.24 mg, 7.5 mmol, 5eq) were dissolved in 300 mL actonirile, and then adjusting the solution to base condition (pH ⁇ 8) by 1 M K 2 CO 3 . A solution of 1 M CuSO 4 (7.5 m, 5eq), and 1 M sodium ascorbate (15 mL, 10eq) was then added, and the reaction mixture was stirred at room temperature for 18 h.
  • reaction mixture was purified by HPLC using the semi-preparative column eluted with 33% acetonitrile acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 1 1.6 min, and the yield of HTK04055 was 55.9 %.
  • ESI- MS calculated [M+H] + C 71 H 101 B 2 F 6 N 1 7 O 19 1632.7628; found [M+H] + 1632.6622.
  • No-carrier-added [ 18 F]fluoride was obtained by bombardment of H 2 18 O with 18-MeV protons (Advanced Cyclotron Systems Inc) followed by trapping on an anion exchange resin column (pre-activated with brine and washed with Dl water). The [ 18 F]fluoride was then eluted from the column using HCI-pyridazine buffer (pH 2.0). Unlabeled trifluoroborate precursor HTK03162 or HTK04055 (100 nmol) was suspended in DMF (15 mL). The eluted [ 18 F]fluoride (30-100 GBq) was added into a reaction vessel containing the solution of HTK03162 or HTK04055.
  • the vial was heated at 80 °C for 20 minutes on a heating block and quenched upon the addition of 1 mL of water.
  • the mixture was purified by the semi-preparative HPLC column and the quality control was performed via the analytical HPLC column with the co-injection of the unlabeled standard. Radiochemical yields (decay-corrected) were >10% and radiochemical purities were >95%.
  • LNCaP cell line was obtained from ATCC (LNCaP clone FGC, CRL-1740). It was established from a metastatic site of left supraclavicular lymph node of human prostatic adenocarcinoma. Cells were cultured in PRM1 1640 medium supplemented with 10 % FBS, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in a humidified incubator containing 5% CO 2 . Cells grown to 80-90% confluence were then washed with sterile phosphate-buffered saline (1 ⁇ PBS pH 7.4), and collected by trypsinization. The collected cell concentration was counted with a Hausser Scientific (Horsham, PA) Hemacytometer.
  • PET/CT, SPECT/CT imaging and biodisthbution studies were performed using NODSCID 1 L2RgKO male mice. Mice were anesthetized by inhalation with 2% isoflurane in oxygen, and implanted subcutaneously with 1 ⁇ 10 7 LNCaP cells behind left shoulder. Mice were imaged or used in biodistribution studies when the tumor grew up to reach 5-8 mm in diameter during 5-6 weeks.
  • PET imaging experiments were conducted using Siemens Inveon micro PET/CT scanner. Each tumor bearing mouse was injected 6 - 8 MBq of Ga-68 or F-18 labeled tracer through the tail vein under anesthesia (2% isoflurane in oxygen). The mice were allowed to recover and roam freely in their cage. After 50 min, the mice were sedated again with 2% isoflurane in oxygen inhalation and positioned in the scanner. A 10-min CT scan was conducted first for localization and attenuation correction after segmentation for reconstructing the PET images. Then, a 10-min static PET imaging was performed to determined uptake in tumor and other organs.
  • SPECT/CT imaging experiments were conducted using the MILabs (Utrecht, the Netherlands) U-SPECT-II/CT scanner. Each tumor bearing mouse was injected with ⁇ 37 MBq of 177 Lu- labeled tracer through the tail vein under anesthesia (2% isoflurane in oxygen). The mice were allowed to recover and roam freely in their cage and imaged at 1 , 4, 24, 72 and 120 hours after injection. At each time point, the mice were sedated again and positioned in the scanner.
  • a 5-min CT scan was conducted first for anatomical reference with a voltage setting at 60 kV and current at 615 mA, followed by a 60-min static emission scan acquired in list mode using an ultra-high resolution multi-pinhole rat- mouse (1 mm pinhole size) collimator.
  • Data were reconstructed using the U-SPECT II software with a 20% window width on three energy windows.
  • the photopeak window was centered at 208 keV, with lower scatter and upper scatter windows centered at 170 and 255 keV, respectively.
  • Reconstruction parameters used maximum-likelihood expectation maximization (3 iterations), pixel-based ordered subset expectation maximization (16 subsets), and a post-processing filter (Gaussian blurring) of 0.5 mm. Images were decay corrected to injection time in PMOD (PMOD Technologies, Switzerland) then converted to DICOM for qualitative visualization in Inveon Research Workplace (Siemens Medical Solutions USA, Inc.).
  • mice were injected with the radiotracer as described above. At predetermined time points (1 h for 68 Ga studies; 1 , 4, 24, 72, or 120 h for 177 Lu studies), the mice was anesthetized with 2% isoflurane inhalation, and euthanized by CO 2 inhalation. Blood was withdrawn immediately from the heart, and the organs/tissues of interest were collected. The collected organs/tissues were weighed and counted using a Perkin Elmer (Waltham, MA) Wizard2 2480 gamma counter.
  • a Perkin Elmer (Waltham, MA) Wizard2 2480 gamma counter.
  • HTK03170 in mice bearing PSMA-expressing LNCaP cancer xenografts bearing PSMA-expressing LNCaP cancer xenografts.
  • Example 1 shows that modifying the Glu sidechain in the Lys-ureido-Glu PSMA-targeting moiety in Formula I, II and III compounds (e.g. by lengthening the Glu sidechain) can significantly decrease the uptake of the tracer in kidney and salivary gland without sacrificing the tumour-to- background contrast ratio in a radiolabeled tracer (compare HTK03041 to HTK03149).
  • the results in Example 2 further confirm that modification of the Glu sidechain provides improved imaging and therapeutic agents for PSMA-expressing diseases/conditions.
  • R 2 is methylene (-CH 2 -) or propylene (-CH 2 -CH 2 -CH 2 -), or their closely related derivatives (e.g. -CH 2 -O-CH 2 -, -CH 2 -S-CH 2 -, or -CH 2 -CHF-), while retaining binding of PSMA-expressing tumors.
  • Example 2 further demonstrate that substituting R 2 with butylene (-CH 2 -CH 2 -CH 2 -CH 2 -), or a derivative thereof, results in poor uptake in PSMA-expressing tumors (see compounds HTK03189A and HTK03189B), indicating that binding to PSMA is severely weakened.
  • Formula I, II and III compounds in which R 2 is a derivative of ethylene can result in reduced kidney and salivary gland uptake while retaining binding of PSMA-expressing tumors, such as when R 2 is substituted ethylene or other ethylene derivative.
  • R 2 is -CH 2 -CHF- (HTK04033 and HTK04040)
  • the present results show that compounds of the invention can still bind well to PSMA and have much less kidney and salivary gland uptake.
  • HTK04040 (the S-isomer) has a relatively higher kidney uptake (76%lD/g), this is still much less than that of HTK03041 (170 %ID/g) , which lacks the fluoro substituent.
  • small substituents e.g. F, CH 3 , OH
  • the results further show that the conjugation of an albumin binder further enhances tumor uptake, resulting in improved tumor-to-kidney and tumor-to-salivary gland uptake ratios, especially at later time points.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/CA2020/050864 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen Ceased WO2020252598A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020227001449A KR20220024595A (ko) 2019-06-21 2020-06-19 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
JP2021576163A JP7618599B2 (ja) 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物
CA3144094A CA3144094A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen
CN202411581546.0A CN119431260A (zh) 2019-06-21 2020-06-19 靶向前列腺特异性膜抗原的放射性标记化合物
AU2020296488A AU2020296488A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen
BR112021025810A BR112021025810A2 (pt) 2019-06-21 2020-06-19 Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
CN202080050494.8A CN114401947B (zh) 2019-06-21 2020-06-19 靶向前列腺特异性膜抗原的放射性标记化合物
EP20825937.4A EP3986872A4 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen
US17/371,587 US11504441B2 (en) 2019-06-21 2021-07-09 Radiolabeled compounds targeting the prostate-specific membrane antigen
IL288960A IL288960B1 (en) 2019-06-21 2021-12-13 Radiolabeled compounds targeting prostate-specific membrane antigen
US17/961,299 US20230114807A1 (en) 2019-06-21 2022-10-06 Radiolabeled compounds targeting the prostate-specific membrane antigen
JP2025002658A JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962865088P 2019-06-21 2019-06-21
US62/865,088 2019-06-21
US202063006643P 2020-04-07 2020-04-07
US63/006,643 2020-04-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/371,587 Continuation US11504441B2 (en) 2019-06-21 2021-07-09 Radiolabeled compounds targeting the prostate-specific membrane antigen

Publications (1)

Publication Number Publication Date
WO2020252598A1 true WO2020252598A1 (en) 2020-12-24

Family

ID=74036930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2020/050864 Ceased WO2020252598A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen

Country Status (10)

Country Link
US (2) US11504441B2 (https=)
EP (1) EP3986872A4 (https=)
JP (2) JP7618599B2 (https=)
KR (1) KR20220024595A (https=)
CN (2) CN114401947B (https=)
AU (1) AU2020296488A1 (https=)
BR (1) BR112021025810A2 (https=)
CA (1) CA3144094A1 (https=)
IL (1) IL288960B1 (https=)
WO (1) WO2020252598A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022126275A1 (en) * 2020-12-16 2022-06-23 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
WO2023164775A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
US12036290B2 (en) 2020-04-09 2024-07-16 Blue Earth Diagnostics Limited Pharmaceutical formulations
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
WO2025055943A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
EP4297804A4 (en) * 2021-02-26 2025-11-26 Telix Pharmaceuticals Innovations Pty Ltd SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVATIVE CONJUGATES (GUL DERIVATIVES) TARGETING PROSTATIC MEMBRANE ANTIGEN (PSA) AND THEIR USE AS PRECURSORS OF THERAPEUTIC AND/OR DIAGNOSTIC AGENTS

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途
CN119101006B (zh) * 2024-09-05 2025-11-07 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性标记物及制法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018223180A1 (en) * 2017-06-06 2018-12-13 The University Of Melbourne Radiopharmaceuticals, radioimaging agents, and uses thereof
WO2019075583A1 (en) * 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
CA2555597C (en) 2004-02-13 2016-06-14 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
ES2847275T3 (es) 2006-11-08 2021-08-02 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
CA2926573C (en) 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
CA2731645C (en) 2007-07-24 2017-05-23 The University Of British Columbia Substituted aryl-fluoroborates as imaging agents
RU2494096C2 (ru) 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2012094334A1 (en) 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
CN103687627A (zh) 2011-03-01 2014-03-26 通用电气健康护理有限公司 作为pet示踪剂的放射性标记的奥曲肽酸类似物
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US20140147381A1 (en) 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2903281C (en) 2013-03-08 2022-11-29 The University Of British Columbia Substituted organofluoroborates as imaging agents
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
WO2015100498A1 (en) 2014-01-03 2015-07-09 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
WO2015135082A1 (en) 2014-03-13 2015-09-17 British Columbia Cancer Agency Branch Bradykinin receptor b1 targeting probes
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
WO2017117687A1 (en) 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
EP3544960A1 (en) 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
CN106967152B (zh) 2017-03-28 2019-11-26 江苏省原子医学研究所 一种氟-18标记的化合物及其制备方法与应用
US11629201B2 (en) 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
WO2020065045A1 (en) 2018-09-28 2020-04-02 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
AU2019407851B8 (en) 2018-12-18 2025-10-09 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018223180A1 (en) * 2017-06-06 2018-12-13 The University Of Melbourne Radiopharmaceuticals, radioimaging agents, and uses thereof
WO2019075583A1 (en) * 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3986872A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
US12427207B2 (en) 2020-04-09 2025-09-30 Blue Earth Diagnostics Limited Pharmaceutical formulations
US12036290B2 (en) 2020-04-09 2024-07-16 Blue Earth Diagnostics Limited Pharmaceutical formulations
WO2022126275A1 (en) * 2020-12-16 2022-06-23 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
CN116981486A (zh) * 2021-01-04 2023-10-31 慕尼黑工业大学 双模式放射性示踪剂和治疗剂
JP2024505374A (ja) * 2021-01-04 2024-02-06 テクニシェ ユニバーシタット ミュンヘン デュアルモード放射性トレーサーおよびその療法
WO2022144467A1 (en) * 2021-01-04 2022-07-07 Technische Universität München Dual mode radiotracer and -therapeutics
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
EP4297804A4 (en) * 2021-02-26 2025-11-26 Telix Pharmaceuticals Innovations Pty Ltd SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVATIVE CONJUGATES (GUL DERIVATIVES) TARGETING PROSTATIC MEMBRANE ANTIGEN (PSA) AND THEIR USE AS PRECURSORS OF THERAPEUTIC AND/OR DIAGNOSTIC AGENTS
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
WO2023164775A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
WO2025055943A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof

Also Published As

Publication number Publication date
JP2022537773A (ja) 2022-08-29
CN114401947B (zh) 2024-11-29
EP3986872A1 (en) 2022-04-27
CA3144094A1 (en) 2020-12-24
AU2020296488A1 (en) 2022-01-20
CN119431260A (zh) 2025-02-14
CN114401947A (zh) 2022-04-26
US20230114807A1 (en) 2023-04-13
IL288960A (en) 2022-02-01
KR20220024595A (ko) 2022-03-03
JP2025069156A (ja) 2025-04-30
US20210338851A1 (en) 2021-11-04
EP3986872A4 (en) 2024-02-21
US11504441B2 (en) 2022-11-22
IL288960B1 (en) 2026-03-01
BR112021025810A2 (pt) 2022-05-10
JP7618599B2 (ja) 2025-01-21

Similar Documents

Publication Publication Date Title
JP7618599B2 (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
US20250186627A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
AU2021366975A1 (en) Novel CXCR4-targeting compounds
WO2022126275A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024016071A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
CN119325480A (zh) 靶向cxcr4的化合物及其制备和使用方法
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
BR122025011654A2 (pt) Compostos radiomarcados de direcionamento de antígeno de membrana específico da próstata, seus usos, composição e método de imageamento
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2026055788A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
US20260077073A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20825937

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3144094

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021576163

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021025810

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227001449

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020296488

Country of ref document: AU

Date of ref document: 20200619

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020825937

Country of ref document: EP

Effective date: 20220121

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021025810

Country of ref document: BR

Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DAS PRIORIDADES US 62/865,088 E US 62/006,643 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO.

ENP Entry into the national phase

Ref document number: 112021025810

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211220

WWD Wipo information: divisional of initial pct application

Ref document number: 202418055010

Country of ref document: IN

WWD Wipo information: divisional of initial pct application

Ref document number: 822483

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 202418055010

Country of ref document: IN